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Summary: In bronchiectasis, P. aeruginosa co-infections occur; bacterial populations both 
adapt and diversify by mutation 
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Abstract  1 
To characterise Pseudomonas aeruginosa populations during chronic lung infections of non-2 
Cystic Fibrosis bronchiectasis patients, we used whole genome sequencing to (i) assess the 3 
diversity of P. aeruginosa and the prevalence of multi-lineage infections, (ii) seek evidence 4 
for cross-infection or common source acquisition and (iii) characterize P. aeruginosa 5 
adaptations. 6 
189 isolates, obtained from the sputa of 91 patients attending 16 adult UK 7 
bronchiectasis centres, were whole genome sequenced. 8 
Bronchiectasis isolates were representative of the wider P. aeruginosa population.  Of 9 
24 patients where multiple isolates were examined, there were seven examples of multi-10 
lineage infections, most likely arising from multiple infection events. The number of 11 
nucleotide variants between genomes of isolates from different patients was in some cases 12 
similar to the variations observed between isolates from individual patients implying the 13 
possible occurrence of cross infection or common source acquisition.  14 
Our data indicate that during infections of bronchiectasis patients, P. aeruginosa 15 
populations adapt by accumulating loss of function mutations, leading to changes in 16 
phenotypes including different modes of iron acquisition and variations in biofilm-associated 17 
polysaccharides. The within-population diversification suggests that larger scale longitudinal 18 
surveillance studies will be required to capture cross infection or common source acquisition 19 
events at an early stage. 20 
 21 
Abstract word count: 196  22 
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Introduction 23 
Bronchiectasis is a chronic, progressive respiratory disease associated with irreversible 24 
widening of the bronchi [1].  Recent data suggest that in the UK incidence rates in women 25 
and men have risen to 35.2 and 26.9 respectively per 100,000 person-years [2].  In the USA 26 
the prevalence of adult bronchiectasis has been estimated at 52 in 100 000 people, with 27 
higher prevalence among women and older individuals [3].  Persistent Pseudomonas 28 
aeruginosa lung infections of bronchiectasis patients, occuring in approximately 30% of 29 
cases, are associated with poorer outcomes and premature mortality [4, 5]. 30 
The study of chronic P. aeruginosa lung infections has focused on cystic fibrosis 31 
(CF)-associated bronchiectasis, where patients are diagnosed, monitored and subjected to 32 
antibiotic therapy from a very early age. This contrasts with non-CF bronchiectasis patients, 33 
who present at a much older age and often have a shorter history of therapeutic interventions. 34 
Hence, bacterial isolates from non-CF bronchiectasis patients exhibit less resistance to 35 
antibiotics compared to isolates from adult CF patients [6]. Previous studies have 36 
characterized the evolution of P. aeruginosa during chronic lung infections in CF patients [7, 37 
8].  More recently, high-resolution analyses have revealed extensive heterogeneity within P. 38 
aeruginosa populations in the CF lung [9-12], including the co-existence of multiple 39 
divergent lineages [13].   40 
In CF, a number of transmissible strains of P. aeruginosa have been identified, 41 
leading to the introduction of measures to control cross infection [14]. The study of P. 42 
aeruginosa in relation to non-CF bronchiectasis is less advanced.  In our single centre study 43 
of 50 P. aeruginosa isolates from 40 bronchiectasis patients using molecular typing, there 44 
was no compelling evidence for cross infection or a dominant clone [15].  However, whole 45 
genome sequence analysis of multiple bronchiectasis isolates has not been carried out. Here, 46 
we report the use of genomics to assess the diversity of P. aeruginosa strains causing 47 
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infections in non-CF bronchiectasis across multiple UK centres, to identify multi-strain 48 
infections, and to look for evidence for cross-infection or common source acquisition.  We 49 
also characterise adaptive mutations and present evidence for within-population divergence 50 
during P. aeruginosa chronic lung infections of bronchiectasis patients.  51 
 52 
Methods 53 
Patients and bacterial isolates 54 
The 189 P. aeruginosa isolates used in this study (see Table S1 in the online supplementary 55 
material) were isolated from sputum samples obtained from 93 patients with bronchiectasis 56 
and chronic P. aeruginosa infection (defined as two or more positive respiratory tract cultures 57 
in the preceding 12 months) attending 16 adult bronchiectasis centres throughout England 58 
and Wales. These included isolates collected as part of a multi-centre nebulized antibiotic 59 
trial [16], where patients were enrolled within 21 days of completing a course of 60 
antipseudomonal antibiotics for an exacerbation. Additional isolates from Newcastle (n = 8) 61 
and Liverpool (n = 53) were collected during observational studies.  The methodology used 62 
for isolating P. aeruginosa from patient sputum samples is described in the online 63 
supplementary material.  64 
For 24 patients, sets of isolates (two or more) from the same sample were analysed to 65 
look for evidence of multi-lineage infections.  For three of these patients (patients 147 – 149), 66 
sets of 14 or 15 isolates from a single sample were sequenced for higher resolution analysis 67 
of within-population heterogeneity. For some analyses, to avoid biases arising from inclusion 68 
of multiple clonal genomes from the same patient, a subset of 99 genomes from 91 patients 69 
was used. This subset consisted of one randomly selected genome per clonal lineage per 70 
patient (see Table S1 in the online supplementary material).  We use the term “clonal 71 
lineage” to describe isolates with shared multilocus sequence type (MLST) profile and 72 
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clustering according to core genome single nucleotide polymorphism (SNP)-based 73 
phylogeny. 74 
 75 
DNA preparation and whole genome sequencing  76 
Details of the extraction of genomic DNA from P. aeruginosa isolates, library preparation 77 
and whole-genome shotgun sequencing using Illumina short read sequencing technology are 78 
given in the online supplementary material. The European Nucleotide Archive accession 79 
number for the study is PRJEB14952. 80 
Methods used for genome sequence assembly, extraction of MLST data, phylogenetic 81 
reconstruction using the core genome, and variant calling by mapping to the genome of 82 
PAO1 [17] to identify single nucleotide polymorphism (SNP) or small insertions or deletions 83 
(INDELs) are described in online supplementary material.   84 
 85 
Identification of large deletions and virulence factor genes 86 
Genome sequences were aligned to the reference genomes P. aeruginosa PAO1 87 
(NC_002516, [17]) and P. aeruginosa LESB58 (FM209186; [18]) and large clone-specific 88 
deletions (10 kb and above) were identified using BRIG [19]. The boundaries of deletions 89 
were determined by aligning the genome sequences with the P. aeruginosa PAO1 genome 90 
using Mauve [20], implemented as part of the Geneious package (www.geneious.com). The 91 
presence and absence of virulence factor genes in genome assemblies was determined using 92 
Blastable (https://www.github.com/bawee/blastable). The Pseudomonas genome database 93 
(beta.pseudomonas.com) [21] was used to facilitate analysis of gene function.  94 
 95 
Results 96 
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Diversity of P. aeruginosa Non-CF BE isolates and evidence for P. aeruginosa multi-97 
lineage co-infections 98 
Core genome SNP phylogenetic analysis alongside a collection of 331 P. aeruginosa isolate 99 
genomes from diverse clinical sources [22], indicated that the bronchiectasis isolates were 100 
widely distributed (see Figure S1 in the online supplementary material). From the 189 101 
isolates, it was possible to extract complete MLST profiles for 160 (see Tables S1 and S2 in 102 
the online supplementary material), with the most widespread sequence types (STs) being 103 
ST-253 (PA14-like [23], 14 patients, 8 centres), ST-179 (7 patients, 4 centres), ST-17 (Clone 104 
C [23], 5 patients, 3 centres), ST-252 (4 patients, 4 centres) and ST-260 (4 patients, 3 105 
centres).  Using core genome SNP phylogeny, previous studies have sub-divided the wider P. 106 
aeruginosa population into two major groups (group I, which includes strain PAO1, and 107 
group II, which includes strain PA14) and one minor group of mostly unrelated clonal 108 
lineages [24, 25].  Of a subset of 99 genomes consisting of one randomly selected genome 109 
per clonal lineage per patient, 71 were located in group I and 27 in group II (Figure 1).  Based 110 
on a combination of MLST genotype and core genome SNP phylogeny, of the 24 patients 111 
from whose samples multiple isolates were examined, there were seven examples of multi-112 
lineage infections.  In one patient (patient 92), three distinct clonal lineages of P. aeruginosa 113 
were identified.  In patients 42, 72, 73, 84, 85 and 148 there were two co-existing lineages 114 
(Figure 1).   115 
 116 
Evidence for shared lineages causing infections in different patients attending the same 117 
centre 118 
The core genome SNP phylogeny identified a number of examples where closely-related 119 
clonal lineages were isolated from more than one patient attending the same centre (see Table 120 
S3 in the online supplementary material).  In order to obtain a higher resolution comparison, 121 
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these isolates were analysed using pairwise comparisons across their entire genomes (Table 122 
S3), identifying five instances where the genomes of isolates from different patients attending 123 
the same centre varied at fewer than 200 sites (C6/C7, C29/C30, C105/109, C139/C141, 124 
C156/C159; Figure 2).  This level of genome similarity is greater than in some pairwise 125 
comparisons of contemporary isolates of the same lineage from the same sputum sample (see 126 
Table S3 in the online supplementary material; from 184 variant sites [C110/C111] to >750 127 
variant sites [C125/C126]). 128 
The draft genome sequences of the sub-set of 99 bronchiectasis isolates were 129 
examined for the presence of large (> 10kb) deletions. A total of 36 different deletions (25 130 
over 100 kb), ranging in size from 11 to 300 kb and representing independent genetic events, 131 
were identified (see Table S4 in the online supplementary material). These were distributed 132 
across 28 genomes in the 99-member genome subset. Most genomes had only one deletion, 133 
although two (C54 and C164) had three deletions and four (A119, C4, C85 and C119) had 134 
two. In most cases, isolates of the same clonal lineages from the same patient shared the same 135 
deletions. However, in patients 45, 55, 79 and 92 not all isolates of the same lineage had the 136 
same deletion.  The genomes of isolate pairs C6/C7, C29/C30, C105/109, C139/C141 and 137 
C156/C159, which are from different patients but vary at fewer than 200 sites (Table 1), were 138 
indistinguishable by BRIG analysis (example shown in Fig. 3B).  139 
 140 
Genomic diversity of isolates within patients can be similar to diversity between patients 141 
In order to further assess the within-patient diversification exhibited by P. aeruginosa 142 
populations, larger sets of isolates from single sputum samples were analysed for three 143 
patients : 147 (15 isolates), 148 (15 isolates) and 149 (14 isolates) (Table 1). For two of these 144 
patients, the P. aeruginosa population was comprised of a single clonal lineage.  For patient 145 
148, two distinct clonal lineages were identified and these two sets of isolates were analysed 146 
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separately.  In all four isolate sets analysed, the maximum pairwise SNP variations between 147 
two isolates of the same lineage exceeded 300, with a median of 179 or greater (Table 1), 148 
indicating the occurrence of within-patient diversification. 149 
  150 
Loss of function mutations and deletions identified in multiple isolates 151 
We used variant calling approaches to identify independent occurrences of loss of function 152 
mutations amongst the sub-set of 99 bronchiectasis isolate genomes.  This yielded a number 153 
of examples of genes with known functions carrying independent loss of function mutations 154 
in multiple isolates (Table 2; see Table S5 in the online supplementary material).  These 155 
include genes linked to mucoidy, virulence, osmoprotection, biofilm formation, motility, 156 
DNA repair and antimicrobial resistance (Table 2).  The genes encoding all three components 157 
of the MexAB-OprM efflux pump appear amongst the most common loss of function 158 
mutations.  Multiple isolates also carried loss of function mutations in genes encoding 159 
regulators (including lasR, algU, fleR, vfr).  Among the 99 bronchiectasis isolates, the 160 
number of genes with loss of function mutations as listed in Table 2 ranged from 0 to 6 (see 161 
Figure S2 and Table S6 in the online supplementary material). 162 
 163 
Hypermutability is a common trait amongst CF isolates of P. aeruginosa.  Of the 99 164 
panel isolates, 11 carried loss of function mutations in the DNA mismatch repair genes, mutS 165 
or mutL (see Table S1 in the online supplementary material).  All but two of these were 166 
confirmed as having the hypermutable phenotype. 167 
  An alignment of all of the genomes containing deletions >10 kb relative to the 168 
genome of strain PAO1 revealed a strikingly non-random distribution, with 30 of the 36 169 
deletions lying within the 1.9 to 2.8 Mb portion of the strain PAO1 genome. Genes within 170 
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this region include the psl genes, encoding an extracellular polysaccharide [26], genes 171 
encoding the siderophore pyoverdine, and genes encoding a type VI secretion apparatus [27]. 172 
 173 
We next specifically examined one representative of each of the 99 clonal lineages for 174 
the presence or absence of genes associated with pathogenicity (see Table S6 in the online 175 
supplementary material).  23 of these genomes lacked one or more of the psl genes. In 176 
contrast, all of the genomes contained all of the alg genes required for making alginate and 177 
the pel genes required for making Pel exopolysaccharide.  Eleven of the genomes lacked 178 
genes required for synthesis of pyoverdine, with nine of these also lacking an fpvA receptor 179 
gene for uptake of ferripyoverdine, although the genes required for synthesis of an alternative 180 
siderophore, pyochelin, were present in all cases. Eleven of the genomes also lacked two or 181 
more genes of the Type VI secretion system [PA2360 (hsiA3) – PA2373 (vgrG3)] (see Table 182 
S6 in the online supplementary material). These findings are consistent with the occurrence 183 
of deletions of the region of the genome containing Psl, pyoverdine and type VI secretion 184 
genes in multiple isolates, although in some isolates smaller deletions (< 10kb) were detected.  185 
 186 
Discussion 187 
We used whole genome sequencing to obtain a cross section of the diversity of P. aeruginosa 188 
strains causing infections in bronchiectasis in the UK.  Our data suggest that the distribution 189 
of P. aeruginosa lineages found amongst the bronchiectasis isolate collection broadly 190 
represents what is present in the global P. aeruginosa population.  In contrast to CF [14], we 191 
found no data to suggest that there is a widespread transmissible strain amongst the UK non-192 
CF bronchiectasis community.  However, our study did not include large numbers of patients 193 
from individual centres.  Lineages such as PA14-like and Clone C, that are naturally more 194 
abundant in nature [23], were also amongst the most abundant in the bronchiectasis 195 
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collection.  Because some lineages are naturally more abundant, their occurrence (based on 196 
MLST) in multiple patients is not necessarily indicative of common source or cross infection.  197 
Whole genome sequencing offers higher resolution than methods such as MLST, allowing us 198 
to address this issue. 199 
In a previous comparison of paired isolates from patients within the same 200 
bronchiectasis centre, in most patients (9 of 10) the two isolates shared a common genotype, 201 
with one patient found to be infected with two strains simultaneously [15].   In this study, of 202 
24 patients from whose samples multiple isolates were examined, seven had multi-lineage 203 
infections.   Similar multi-lineage infections have also been reported in CF, generally 204 
associated with children [28].  A number of studies in CF have also demonstrated the 205 
phenotypic [9, 11, 12] and genomic [10, 13, 29] diversification of single lineage P. 206 
aeruginosa populations in the CF lung.  Here, we show for the first time that similar 207 
diversification occurs during infections of non-CF bronchiectasis patients.  Both the 208 
prevalence of multi-lineage infections, and the diversification that occurs during the infection 209 
process emphasise the need to be cautious when interpreting the analysis of sputum samples 210 
based on single isolates of P. aeruginosa. 211 
We found several examples of isolates from patients attending the same centre, that 212 
not only shared the same clonal lineage, but also differed genomically by <200 sites.  213 
Genomic variations between isolates from the same patient sample revealed similar, and in 214 
some cases higher, levels of variation.  The occurrence of isolates with very high genetic 215 
relatedness in different patients strongly implies that there has been common source 216 
acquisition or cross infection.  The extent of the nucleotide variations differentiating two 217 
isolates will be dependent upon (i) the length of time since the transmission event and (ii) the 218 
rate of mutation of the P. aeruginosa population during the infection.  Further studies will be 219 
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needed to better define the role of cross infection or common source acquisitions in this 220 
patient group. 221 
There was clear evidence for bacterial adaptation to the lung environment by the 222 
accumulation of mutations and deletions, including loss of function mutations in genes 223 
identified previously as being commonly mutated in CF, such as mucA (mucoidy) and lasR 224 
(quorum sensing). It is worth noting, however, that mutations in genes encoding some of the 225 
regulators highlighted in previous CF studies (mexT, retS, exsD, ampR) were observed either 226 
infrequently (two mexT and two ampR mutants) or not at all (see Table S5 in the online 227 
supplementary material).  Mutations in global regulators potentially affect numerous 228 
processes. In CF, the pathoadaptive genes identified in different studies have varied, 229 
suggesting that there are multiple routes to adaptation to the CF lung [7, 8], a scenario which 230 
is likely to apply also to non-CF bronchiectasis. 231 
Loss of function mutations in genes encoding the MexAB-OprM efflux pump were 232 
common amongst the bronchiectasis isolates.  Although generally thought of as a multidrug 233 
efflux system important for antibiotic resistance, this system has also been implicated in 234 
virulence [30]. Hence, although it may seem counterintuitive that P. aeruginosa should adapt 235 
by losing an antibiotic resistance-related efflux pump, it may be that the driver for selection is 236 
related to a function other than antibiotic efflux.  In contrast, the loss of function mutations in 237 
mexS can be linked directly to antibiotic resistance, since mutations in mexS promote 238 
upregulation of the MexEF-OprN MDR efflux pump [31].  239 
The prevalence amongst non-CF BE isolates of deletions in a specific genomic region 240 
encoding pyoverdine and Psl polysaccharide was higher than in a dataset of 331 P. 241 
aeruginosa clinical isolate genomes [22], where 22 genomes lacked one or more psl genes, 242 
only three lacked one or more of the pyoverdine synthesis genes, and only one did not have 243 
an fpvA receptor gene. P. aeruginosa can utilise multiple pathways for iron acquisition [32]. 244 
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During chronic lung infections in CF, P. aeruginosa adapts by favouring the heme utilisation 245 
route for iron acquisition rather than the pyoverdine siderophore system [33].  Our 246 
observations suggest a similar adaptation in non-CF bronchiectasis.  247 
In order to protect itself from hostile environmental conditions or host defences P. 248 
aeruginosa can produce three exopolysaccharides contributing to biofilm formation: alginate, 249 
Psl and Pel [26].  It has been suggested that Psl is a key surface attachment determinant [34], 250 
whereas in the CF lung free-floating biofilm structures may be more important [35]. Other 251 
mutations favouring the production of Pel rather than Psl include mutations in bifA [36], rbdA 252 
[37], oprF [38] and ladS [39].  Hence, overall our observations indicate that in non-CF BE 253 
chronic lung infections, the Pel and alginate exopolysaccharides are favoured over Psl. 254 
Other common loss of function mutations (in pilJ, chpA and fimV) are implicated in 255 
lost or amended twitching motility, an adaptation also seen both in CF [8] and in an artificial 256 
sputum biofilm model [40], suggesting that this may be an adaptation related to the viscosity 257 
of the sputum environment.  258 
Our study represents the first comparative genomics analysis of multiple P. 259 
aeruginosa isolates associated with chronic lung infections of non-CF bronchiectasis patients.  260 
Although a larger, more targeted study, analysing greater numbers of isolates per sample, 261 
would be needed to determine the true prevalence of multi-lineage infections, this 262 
observation does suggest that it is common for multiple P. aeruginosa lineages to co-exist in 263 
bronchiectasis infections.  Our study also demonstrates that within-sample diversity can be 264 
comparable in scale to the genetic variations that occur between isolates from different 265 
patients attending the same centre. These observations suggest that there is an urgent need for 266 
more detailed and larger scale longitudinal studies in non-CF patients, and for surveillance 267 
that captures the diversity within centres and would identify cross infection or common 268 
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source acquisition events earlier, allowing measures to be taken in order to minimise the 269 
spread of this important pathogen. 270 
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 280 
Figure legends. 281 
Figure 1. Evidence for multi-lineage co-infections in seven patients.  The figure shows a 282 
core genome SNP phylogeny for the sub-set of 99 isolates, confirming that all but one isolate 283 
(B113) clusters into one of two major groups. Each bronchiectasis centre is represented by a 284 
different colour.  Arrows sharing the same colour indicate isolates that were obtained from 285 
the same patient.  The three isolates from the same patient 92 sample are numbered 1-3. 286 
 287 
Figure 2. Example pairwise comparisons between isolates sharing the same clonal 288 
lineage that were isolated from more than one patient attending the same centre.  The 289 
number of SNP variations are indicated, with the number of IN-DEL variations shown in 290 
brackets.  Full details are shown in Table S3 in the online supplementary material.  The five 291 
examples where isolates shared fewer than 200 variant sites are highlighted in green.  All 292 
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isolates of ST-244 from patients attending Centre 4 were compared, with similarity graded 293 
according to variant sites (<200, green; 200 – 3000 orange; >3000 red).   294 
 295 
Figure 3. Examples of alignment of genomes of bronchiectasis strains with that of 296 
reference strain P. aeruginosa PAO1. Sequences identified as present (dark grey) or absent 297 
(white) in the genome of PAO1 are indicated. (A) Isolates of the same lineage (ST-253) from 298 
the same patient. From innermost to outermost, C95, C97, C98, C99, C96. A deletion present 299 
in isolate C96 only is highlighted (see arrow). (B) Pairs of isolates (from innermost to 300 
outermost C6 and C7; and C156 and C159) that both share the same clonal lineage but are 301 
from different patients attending the same hospital. Isolates C6 and C7 share a large deletion 302 
and isolates C156 and C159 share a smaller overlapping deletion (Supplementary Table S4), 303 
as indicated (see arrows). (C) Isolates of different lineages from the same patient. From 304 
innermost to outermost, A77, A80, A85 (all ST-175); A78, A81, A82 (all ST-17). A large 305 
deletion present in the ST-17 isolates is indicated by an arrow. The figures were generated 306 
using BRIG. 307 
 308 
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Table 1.  Summary of genomic diversity observed within the same clonal lineage of P. aeruginosa in individual patients 
  
Patient 
Number 
of isolates 
Mean 
SNPs 
Median 
SNPs 
SNP 
range 
Mean 
Indels 
Median 
Indels 
Indel 
range 
Patient 147  15 336.35 261.00 88-640 15.20 14.00 0-35 
Patient 148 (ST17)  4 451.50 482.50 159-654 23.83 25.50 6-34 
Patient 148 (ST175)  11 195.45 179.00 79-403 9.27 5.00 0-36 
Patient 149 14 209.01 206.00 68-327 11.40 10.00 3-28 
 
The table indicates the number of single nucleotide polymorphisms (SNPs) and small insertion and deletion (INDEL) differences between the 
genomes of contemporary isolates from single sputum samples.   
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Table 2 Loss of function mutations occurring in multiple isolates.   Only mutations predicted to lead to loss of function were included (ie. 
introduction of a stop codon, or a frame-shift mutation).  The number of independent mutations indicates the number of isolates carrying unique 
mutations in the listed gene.  The Table shows those genes where the number of independent occurrences of a mutation was equal to or greater 
than five. 
 
Gene PAO1 
gene 
number 
Number of 
independent 
occurrences 
of a 
mutation 
Function / Comment 
mexB PA0426 16 Transporter from MexAB-OprM efflux pump, antibiotic resistance, virulence 
mucA PA0763 13 Anti-sigma factor, mutations can lead to mucoidy.  
betT2  PA5291 9 Transporter, uptake of small molecules such as choline and glycine betaine, contributing to 
growth via phosphatidyl choline metabolism and osmoprotection  
bifA PA4367 7 Cyclic-di-GMP phosphodiesterase, inversely regulates biofilm formation 
mexA PA0425 7 Membrane fusion protein from MexAB-OprM efflux pump, antibiotic resistance, virulence 
pcoA PA2065 7 Copper resistance 
PA4469 PA4469 7 Hypothetical protein encoded by a gene in same operon as and upstream of sodM 
(superoxide dismutase; response to oxidative stress) 
rbdA PA0861 7 Cyclic-di-GMP phosphodiesterase, modulation of biofilm dispersal, negative regulation of 
Pel production 
pilJ PA0411 6 Methyl accepting chemotaxis receptor-like protein involved in twitching motility and 
biofilm formation 
oprM PA0427 6 Outer membrane protein from MexAB-OprM efflux pump, antibiotic resistance, virulence 
oprF PA1777 6 Major porin, biofilm formation 
chpA PA0413 5 Chemotaxis-like chemosensory protein involved in twitching motility 
fimV PA3115 5 Peptidoglycan-binding protein, promotes type IV pilin assembly, twitching motility 
ladS PA3974 5 Sensor kinase, implicated in switch between acute and chronic infection 
mutL PA4946 5 Mismatch repair system, DNA repair, mutation can lead to mutator phenotype 
gmd PA5453 5 GDP-mannose 4,6-dehydratase,  
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mexS PA2491 5 Mutations promote MexT-dependent mexEF-oprN expression and multidrug resistance 
pchE PA4226 5 Pyochelin synthesis  
PA0054 PA0054 5 Hypothetical protein 
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Centre 4 (ST-244) 
Patient: 38 39 40 40 40 
Isolate C6 C7 C8 C9 C10 
C6 179(8) 3790(79) 3733(74) 3833(62) 
C7 3736(82) 3714(75) 3929(65) 
C8 281(5) 603(14) 
C9 515(11) 
Centre 15 (ST-252) 
Patient: 48 49 
Isolate C29 C30 
C29 168(3) 
Centre 13 (ST-840) 
Patient: 83 85 
Isolate C105 C109 
C105 131(8) 
Centre 16 (ST-260) 
Patient: 108 110 
Isolate C156 C159 
C156 160(3) 
  Centre 14 (ST-2102) 
Patient: 98 99 
Isolate C139 C141 
C105 177(3) 
Page 23 of 81 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
AB
C
Page 24 of 81European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
0.01
Color ranges:
Bronchiectasis isolates
Reference_strains
AZPAE148812135
AZPAE148902147AZPAE148802134
AZPAE144032363
AZPAE143942360
A107
A106
A97
A95
A92
A91
A90
A86
A85
A80
A77
AZPAE149092091
AZPAE147222386
AZPAE150102237
AZPAE121362383
AZPAE121442389
AZPAE150142241
AZPAE121522398
AZPAE148282336
AZPAE1481
32323
AZPAE1489
72156
AZPAE150302
197
AZPAE121542400
AZPAE149862214
AZPAE150322179
AZPAE150502184
AZPAE124092402
AZPAE148192328
AZPAE148212330
AZPAE148222331
AZPAE148532108
AZPAE149232162
AZPAE
144412
370AZP
AE150
552251
C12
C11A
ZPAE146
982308
AZPAE150
282209
AZPA
E149
3622
64AZPA
E1499
62223AZP
AE14
69723
07AZPAE
14859
2115
C57
C58
C56
C55
C59
C60
AZ
PA
E12
145
239
1
AZP
AE1
241
924
14
AZP
AE1
213
823
81
AZP
AE1
5060
2254
AZP
AE1
4499
2375AZP
AE1
4570
2298AZP
AE14
9402
278AZPA
E149
9822
25AZPA
E150
4422
00
AZ
PA
E1
48
48
21
04
AZ
PA
E1
50
56
22
50
AZ
PA
E1
49
43
21
69
AZ
PA
E1
213
723
84
AZ
PA
E1
439
023
58
AZ
PA
E1
487
521
29
B
3
A
ZP
A
E
14
96
12
18
7
C
15
8
AZ
PA
E1
48
23
23
32
C
15
3
C
33
AZ
PA
E1
50
69
22
62
C
31
A
ZP
A
E
14
92
42
16
3
C
32
AZ
PA
E1
47
15
23
90
C1
08
AZ
PA
E1
21
50
23
96
C1
8
C8
5
AZ
PA
E1
49
53
21
81
A1
2C
87C
10
6C1
15
B3
4C1
04C
11
0C1
11C
11
2C
11
4
AZ
PA
E1
45
66
22
99
AZ
PA
E1
47
11
24
17
AZ
PA
E1
49
45
21
72
C
5
4
A
Z
P
A
E
1
4
5
0
5
2
3
7
6
A
Z
P
A
E
1
4
8
2
0
2
3
2
9
A
Z
P
A
E
1
4
8
3
5
2
2
9
1
A
Z
P
A
E
1
4
8
3
7
2
2
9
3
A
Z
P
A
E
14
88
62
14
2
A
Z
P
A
E
15
06
62
26
0
A
Z
P
A
E
14
55
42
29
5
A
Z
P
A
E
15
00
72
23
4
A
Z
P
A
E
14
53
52
37
9
A
Z
P
A
E
15
00
92
23
6
A
Z
P
A
E
14
38
12
35
6
A
Z
P
A
E
15
00
22
22
9
A
Z
P
A
E
14
45
32
37
3
A
Z
P
A
E
14
84
62
10
1
A
Z
P
A
E
14
98
32
21
1
A
Z
P
A
E
14
41
52
36
6
A
ZP
A
E
14
46
32
37
4
A
ZP
A
E
14
72
42
35
4
A
ZP
A
E
14
72
92
31
6
A
ZP
A
E
14
93
32
28
5
A
Z
P
A
E
1
4
9
0
7
2
2
6
8
A
Z
P
A
E
1
4
9
5
2
2
1
8
0
A
Z
P
A
E
1
4
5
5
0
2
2
9
6
A
Z
P
A
E
1
4
9
1
8
2
0
9
3
A
Z
P
A
E
1
4
8
6
8
2
1
2
3
C
1
6
1
A
Z
P
A
E
1
4
9
4
6
2
1
7
4
C
6
3C
1
5
A
Z
P
A
E
1
2
1
3
5
2
3
8
2
C
1
4
C
1
3
A
Z
P
A
E
1
4
8
4
4
2
0
9
8
C
1
2
3
A
Z
P
A
E
1
2
1
4
7
2
3
9
4
C
1
6
C
1
7
C
8
9
A
Z
P
A
E
1
2
4
1
0
2
4
0
4
A
Z
P
A
E
1
4
8
9
1
2
1
4
8
A
Z
P
A
E
1
4
9
9
5
2
2
2
2C
7
4
A
Z
P
A
E
1
4
8
6
6
2
1
2
1
A
Z
P
A
E
1
2
4
1
7
2
4
1
2
A
Z
P
A
E
1
4
8
1
0
2
3
2
0
A
Z
P
A
E
1
4
8
6
1
2
1
1
7
A
Z
P
A
E
1
4
9
2
1
2
2
7
3
A
Z
P
A
E
1
5
0
6
1
2
2
5
6
A
Z
P
A
E
1
4
9
0
8
2
2
7
2
B
6
2
A
Z
P
A
E
1
4
6
9
3
2
3
0
4
A
Z
P
A
E
1
4
9
6
3
2
1
8
9
C
1
5
5
A
Z
P
A
E
1
4
5
3
8
2
3
8
0
C
1
1
6
C
1
2
9
C
1
1
8
C
1
1
7
A
Z
P
A
E
1
4
5
2
6
2
3
7
8
A
Z
P
A
E
1
4
8
8
2
2
1
3
7
A
Z
P
A
E
1
5
0
2
9
2
2
0
4
A
Z
P
A
E
1
4
9
8
4
2
2
1
2
A
Z
P
A
E
1
3
8
7
7
2
3
4
6
A
Z
P
A
E
1
4
8
1
1
2
3
2
1
A
Z
P
A
E
1
4
9
2
2
2
1
6
1
A
Z
P
A
E
1
4
9
2
9
2
0
9
2
A
Z
P
A
E
1
4
9
4
2
2
2
8
2
C
2
1
C
2
2
C
2
3
A
Z
P
A
E
1
4
9
1
3
2
2
7
4
A
Z
P
A
E
1
4
9
2
5
2
1
6
5
A
Z
P
A
E
1
4
8
5
5
2
1
0
9
A
Z
P
A
E
1
2
4
1
1
2
4
0
5
A
Z
P
A
E
1
4
9
9
9
2
2
2
6
C
1
0
2
C
1
0
3
C
1
0
1
A
Z
P
A
E
1
4
8
9
9
2
1
5
8
A
Z
P
A
E
1
2
4
2
3
2
4
1
8
A
Z
P
A
E
1
2
4
1
6
2
4
1
0
A
Z
P
A
E
1
2
4
1
8
2
4
1
3
C
1
0
0
A
Z
P
A
E
1
4
8
6
4
2
1
1
9
A
Z
P
A
E
1
2
1
4
9
2
3
9
3
A
Z
P
A
E
1
4
9
3
4
2
2
7
7
A
Z
P
A
E
1
4
9
1
6
2
2
8
1
A
Z
P
A
E
1
4
9
2
8
2
1
6
8
A
Z
P
A
E
1
4
9
5
4
2
1
8
2
A
Z
P
A
E
1
4
6
8
8
2
3
0
0
A
Z
P
A
E
1
4
8
0
9
2
3
1
9
A
Z
P
A
E
1
4
9
7
6
2
2
0
3
C
1
2
8
C
1
2
7
A
Z
P
A
E
1
2
4
2
2
2
4
1
6
A
Z
P
A
E
1
5
0
0
1
2
2
2
8
A
Z
P
A
E
1
4
8
5
2
2
1
0
6
A
Z
P
A
E
1
5
0
4
6
2
1
2
4
A
Z
P
A
E
1
4
8
2
4
2
3
3
3
A
Z
P
A
E
1
4
9
6
4
2
1
9
0
A
Z
P
A
E
1
4
9
6
5
2
1
9
3
A
Z
P
A
E
1
5
0
7
0
2
2
6
3
A
Z
P
A
E
1
4
8
5
1
2
1
0
5
C
4
9
A
Z
P
A
E
1
5
0
3
7
2
1
1
0
C
1
4
7
C
9
4
C
1
4
6
C
1
4
8
A
Z
P
A
E
1
4
8
1
4
2
3
2
4
A
Z
P
A
E
1
4
8
1
5
2
3
2
5
A
Z
P
A
E
1
4
8
9
3
2
1
5
0
A
Z
P
A
E
1
4
9
7
3
2
2
0
1
A
Z
P
A
E
1
4
9
9
7
2
2
2
4
A
Z
P
A
E
1
5
0
3
1
2
1
9
1
C159AZPAE148392294
C156
C5
C4
C3
AZPAE149552183
C137
AZPAE148762130
AZPAE121562401
AZPAE150492090
AZPAE148472102
AZPAE149752202
A
ZP
A
E
147042313
A
ZP
A
E
148792133
A
ZP
A
E
150382118
A
ZP
A
E
121532399
A
ZP
A
E
150232249
AZPAE150572252
AZPAE150222248
AZPAE148172326
AZPAE144432372
A
ZP
A
E
148772132
A
ZP
A
E
149712198
A
Z
P
A
E
124122406
A
Z
P
A
E
150402151
C
67AZ
P
A
E
150722259
C
64C65C68C66AZ
P
A
E
149142276
A
Z
P
A
E
149262166
A
Z
P
A
E
149812208
A
Z
P
A
E
150332269
AZPAE149312271
A36A163
LESB58
AZPAE137572337
C51
C78C109
C105
AZPAE121402385
AZPAE124152409
AZPAE124132407
AZPAE124142408
A19
AZPAE150532138PAO1107
AZPAE144102365
C20
AZPAE149472283
AZPAE150522175
AZPAE144022362
AZPAE149172266
AZPAE149152107
AZPAE149272167
AZPAE148412094
AZPAE148672122
C6
C7
C10
C8
C9
AZPAE150132240
AZPAE138642343
AZPAE149582185
AZPAE149782206
AZPAE148332290
AZPAE148342289
AZPAE150212247
B114
AZPAE148182327
C120
AZPAE148732127AZPAE149102112
C151
C160
AZPAE
143522
349
AZPAE1
488521
41
C69
AZPAE149
922219
AZPAE1
483622
92
C71
AZPAE148952
153
AZPAE149
772205
C135
C142
AZPAE145572297
C30
C92
C29
AZPAE150122239
A3
A4
A5
AZPAE124202415
AZPA
E146
9123
03
AZPA
E121
5123
97
AZPA
E1488
42140
AZP
AE1
4930
2275
C164
C139
C141
AZP
AE1
2143
2388
AZP
AE
121
422
387
AZP
AE1
506
222
55AZ
PA
E14
825
233
4
AZP
AE1
214
623
92
AZP
AE1
485
621
11
C43
C44
C14
9
C45
AZ
PA
E15
036
209
7
A8
1
A1
00
A7
8
AZ
PA
E1
50
68
22
61
A1
A4
6
A4
8
A5
2
A5
3
A5
4
A5
5
A5
6
A5
8
A6
0
A7
0
A7
1
A7
2
A7
3
A7
5
C7
3
A7
6
A8
2
C1
68
AZ
PA
E1
21
48
23
95
AZ
PA
E1
47
25
23
14
AZ
PA
E1
48
57
21
13
AZ
PA
E1
49
35
22
86
AZ
PA
E1
49
44
21
73
AZ
PA
E1
495
021
78
AZ
PA
E1
499
322
20
AZ
PA
E1
501
822
45
A
ZP
A
E
14
96
72
19
2
A
ZP
A
E
15
04
12
14
4
A
154
A
156A
151A148A147A144A141A137A134A130A126A123
A119
A122
AZPAE143732355
AZPAE149822210
C124
C119
B199
C88
A
ZP
A
E
148832139
A
ZP
A
E
150642258
A
Z
P
A
E
149002159
A
Z
P
A
E
149892217
A
Z
P
A
E
148652120
A
ZP
A
E
149202270
A
Z
P
A
E
1
4
9
6
9
2
1
9
5
A
Z
P
A
E
1
4
9
7
0
2
1
9
6
A
Z
P
A
E
1
4
9
3
8
2
2
6
5
A
Z
P
A
E
1
4
8
9
4
2
1
5
2
A
Z
P
A
E
1
4
8
6
0
2
1
1
6
A
Z
P
A
E
1
4
8
2
9
2
2
8
8
A
Z
P
A
E
148262335
A
Z
P
A
E
147162342
A
Z
P
A
E
147122411
A
Z
P
A
E
150052232
A
Z
P
A
E
148122322
C
77
C
86
A
Z
P
A
E
138532340
A
Z
P
A
E
138582341
A
Z
P
A
E
1
4
9
7
2
2
1
9
9
A
Z
P
A
E
1
4
9
8
7
2
2
1
5
A
Z
P
A
E
1
5
0
3
4
2
2
7
9
A
Z
P
A
E
1
4
8
7
0
2
1
2
5
A
Z
P
A
E
1
5
0
4
3
2
1
4
5
A
Z
P
A
E
1
3
8
7
6
2
3
4
5
A
Z
P
A
E
1
5
0
5
4
2
1
7
1
A
Z
P
A
E
1
4
4
3
7
2
3
6
9
A
Z
P
A
E
1
3
8
4
8
2
3
3
8
A
Z
P
A
E
1
4
9
9
1
2
2
1
8
A
Z
P
A
E
1
4
4
0
4
2
3
6
4
A
Z
P
A
E
1
5
0
1
9
2
2
4
6
A
Z
P
A
E
1
5
0
3
9
2
1
2
6
A
Z
P
A
E
1
4
7
0
0
2
3
1
0
C
4
2
A
Z
P
A
E
1
4
6
9
2
2
3
0
2
A
Z
P
A
E
1
4
3
9
5
2
3
6
1
A
Z
P
A
E
1
4
9
8
5
2
2
1
3
A
Z
P
A
E
1
4
9
8
8
2
2
1
6
A
Z
P
A
E
1
4
9
3
2
2
2
6
7
A
Z
P
A
E
1
5
0
5
9
2
2
5
3
A
Z
P
A
E
1
4
3
9
3
2
3
5
9
A
Z
P
A
E
1
4
3
5
9
2
3
5
1
A
Z
P
A
E
1
4
8
9
2
2
1
4
9
A
Z
P
A
E
1
4
5
0
9
2
3
7
7
A
2
A
Z
P
A
E
1
5
0
2
6
2
1
7
0
A
Z
P
A
E
1
5
0
2
7
2
1
6
4
A
Z
P
A
E
1
4
8
5
8
2
1
1
4
A
Z
P
A
E
1
5
0
0
8
2
2
3
5
A
Z
P
A
E
1
4
8
8
9
2
1
4
6
A
Z
P
A
E
1
4
9
5
9
2
1
8
6
A
Z
P
A
E
1
4
9
1
1
2
2
8
0
A
Z
P
A
E
1
4
9
6
2
2
1
8
8
A
Z
P
A
E
1
5
0
0
4
2
2
3
1
A
Z
P
A
E
1
4
4
4
2
2
3
7
1
C
8
3
C
6
1
C
8
0
C
7
9
C
8
1
C
8
4
C
8
2
B
3
7
C
1
6
7
C
9
9
C
1
4
4
C
9
8
C
9
7
C
9
5
C
1
3
4
C
1
3
3
C
9
6
C
1
4
5
C
3
6
C
1
4
3
C
9
1
U
C
B
P
P
P
A
1
4
1
0
9
A
Z
P
A
E
1
4
8
5
0
2
1
0
3
A
Z
P
A
E
1
5
0
2
4
2
1
3
6
A
Z
P
A
E
1
4
6
9
9
2
3
0
9
C
2
A
Z
P
A
E
1
4
8
9
8
2
1
5
7
A
Z
P
A
E
1
4
8
4
5
2
0
9
9
A
Z
P
A
E
1
5
0
1
1
2
2
3
8
C
1
3
1
B
1
6
C
7
6
C
1
2
5
C
1
2
6
C
1
5
0
C
1
0
7
A
Z
P
A
E
1
4
6
9
5
2
3
0
6
A
Z
P
A
E
1
4
9
4
8
2
1
7
6
A
Z
P
A
E
1
5
0
1
6
2
2
4
2
A
Z
P
A
E
1
5
0
2
5
2
1
5
5
A
Z
P
A
E
1
5
0
4
5
2
1
5
4
C
2
5
A
Z
P
A
E
1
4
7
2
6
2
3
1
5
A
Z
P
A
E
1
3
8
7
9
2
3
4
7
A
Z
P
A
E
1
4
8
7
4
2
1
2
8
A
Z
P
A
E
1
4
7
3
0
2
3
1
7
A
Z
P
A
E
1
4
3
5
3
2
3
5
0
A
Z
P
A
E
1
4
6
9
0
2
3
0
1
A
Z
P
A
E
1
4
7
2
3
2
3
4
8
A
Z
P
A
E
1
3
8
5
0
2
3
3
9
A
Z
P
A
E
1
5
0
6
3
2
2
5
7
A
Z
P
A
E
1
4
4
2
2
2
3
6
7
A
Z
P
A
E
1
4
6
9
4
2
3
0
5
A
Z
P
A
E
1
4
7
0
2
2
3
1
1
A
Z
P
A
E
1
4
7
0
3
2
3
1
2
A
Z
P
A
E
1
4
7
0
5
2
3
5
2
A
Z
P
A
E
1
4
7
0
8
2
3
5
3
A
Z
P
A
E
1
4
7
1
0
2
3
4
4
A
Z
P
A
E
14
71
92
40
3
A
Z
P
A
E
14
72
02
35
7
A
Z
P
A
E
14
72
12
36
8
A
Z
P
A
E
14
73
22
31
8
A
Z
P
A
E
14
83
02
28
7
A
Z
P
A
E
14
84
22
09
5
A
Z
P
A
E
14
84
32
09
6
A
Z
P
A
E
14
88
72
14
3
A
Z
P
A
E
14
90
22
16
0
A
Z
P
A
E
14
91
22
28
4
A
Z
P
A
E
14
94
92
17
7
A
Z
P
A
E
14
96
82
19
4
A
ZP
A
E
14
97
92
20
7
A
ZP
A
E
15
00
02
22
7
A
ZP
A
E
15
00
32
23
0
A
ZP
A
E
15
00
62
23
3
A
ZP
A
E
15
01
52
24
3
AZPAE149942221
AZPAE150172244
B113
AZPAE150422131
PA7
AZPAE149412100
Page 25 of 81 European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Online Supplementary Material for: 
 
Pseudomonas aeruginosa adaptation and diversification in the non-Cystic Fibrosis 
bronchiectasis lung  
 
Yasmin Hilliam, Matthew P. Moore, Iain L. Lamont, Diana Bilton, Charles S. Haworth, 
Juliet Foweraker, Martin J. Walshaw, David Williams, Joanne L. Fothergill, Anthony 
De Soyza, Craig Winstanley 
 
Supplementary Methods 
 
Isolation of P. aeruginosa from sputum samples 
All samples were cultured for routine quantitative microbiology. Sputum was homogenised 
with equal parts of 0.1% (v/v) dithiothreitol, and the homogenised sample was diluted in 
sterile distilled water to 1 in 200 and 1 in 10,000. Both dilutions were spread by Whitley 
Automatic Spiral Plater (WASP) onto agar plates.  Cultures on Columbia blood agar, 
chocolate agar and cysteine lactose electrolyte deficient agar (CLED) were incubated at 37
o
C 
in 5% (v/v) CO2  for up to 48 h. Cultures on Pseudomonas agar plus CFC supplement 
(PCFC)  were incubated at 37
o
C in air for up to 48 h and then checked for small colony 
variants (SCV) after incubating on the bench for up to a further 48 h. Colony forming unit 
(CFU) representatives of up to four colonial morphotypes were sub cultured and stored in 
15% (v/v) Glycerol for  archiving  at -80
o
C. 
 
DNA preparation and genome sequencing  
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Genomic DNA was extracted from isolates using a Promega Wizard Genomic DNA 
Purification Kit, quantified using a Qubit 3.0 fluoromiter (Qubit dsDNA broad range assay 
kit, Life Technologies) and tested for purity using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific).  Library preparation and whole-genome shotgun sequencing was 
performed by the Centre for Genomic Research at the University of Liverpool, UK using 
Illumina short read sequencing technology.  Shotgun libraries were prepared from the 
normalised samples using TruSeq Nano library preparation kit. Following library preparation, 
paired-end sequencing (2 x 100 bp) was performed by multiplexing into one lane of the 
Illumina HiSeq platform and sequenced with SBS V4 chemistry. 
Following processing, the raw Fastq files were trimmed for the presence of Illumina 
adapter sequences using Cutadapt version 1.2.1 [1].  The option –O 3 was used so that the 3ʹ 
end of any reads which match the adapter sequence for 3 bp or more were trimmed. The reads 
were further trimmed using Sickle (https://github.com/najoshi/sickle) version 1.200 with a 
minimum window quality score of 20. Reads shorter than 10 bp after trimming were 
removed. If only one read of a pair passed this filter, it was included in the R0 file, with files 
R1 and R2 containing corresponding paired-end sequences.  Quality filtered and adapter 
trimmed short reads were de novo assembled and scaffolded using the A5 MiSeq assembler 
[2].  Genome assembly quality metrics such as N50, largest contig, and overall number of 
contigs were produced using QUAST [3]. 
 
Core genome SNP phylogeny 
The core genome was extracted using Panseq [4] and was defined as 500 bp fragments of all 
genomes in this study which matched with at least 85% similarity. A phylogenetic tree was 
approximated from core genome polymorphic sites, not including gaps or ambiguous bases 
by maximum likelihood with inner node bootstrap (n = 1000) and 10 discrete gamma 
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categories. All phylogenetic analyses were performed using MEGA6 [5] and visualised using 
the iTOL software [6]. Long branches were reduced for clarity.  
 
Multilocus Sequence Typing 
MLST profiles were extracted based on the pubMLST Pseudomonas aeruginosa scheme 
(http://pubmlst.org/paeruginosa/) using a specific tool (https://github.com/tseemann/mlst).  
It was not possible to extract complete MLST profiles from all genomes.  In the context of 
this study, a lineage is defined on the basis of MLST profile and core genome SNP 
phylogeny. 
 
Whole genome pairwise comparisons 
Pairwise comparisons between assembled genomes were performed using MUMmer 3.0 [7].  
Any positions in the alignment with ambiguous nucleotides were removed.  
 
Read mapping and variant calling  
All genome short read files (fastq) were mapped to reference genome PAO1  [8] using bwa-
075a (mem) [9] producing a sequence alignment map (sam) files which were converted to 
binary alignment map files (bam) using picard tools-1.85 
(https://broadinstitute.github.io/picard/). The reference genome was first indexed and sorted 
using bwa and SAMtools [10] respectively and a sequence dictionary created using picard 
tools-1.85. Variants were called following the Genome Analysis Toolkit (GATK) best 
practices workflow, as follows: duplicates were marked, the bam file indexed and sorted with 
picard tools-1.85, realignment targets created, INDELs realigned with GATK-3.3 [11] and 
variants called with the HaplotypeCaller module. Variants were filtered using vcffilter 
(https://github.com/vcflib/vcflib) with the standard parameters (DP >9, QUAL >10).  
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 Resulting variant call files (vcf) were annotated to predict functional outcomes of variants 
compared with PAO1 genes using SnpEff [12]. Using SAMtools depth any variants within 
genes to which short reads had not aligned to 100% of its length were excluded from further 
analysis, leaving substitutions and short insertions or deletions (INDELs) and eliminating 
genes from functional variant analysis to which reads did not fully align due to sequencing 
error (lack of coverage) or genuine large deletions/complete absence.  
 
Loss of function mutations  
 
Predicted loss of function mutations were inferred to have been acquired independently in the 
population if they differed by position or type between genomes. Where the position and type 
were the same they were inferred to be shared; in genes where a mutation was shared with 
other genomes, further loss of function mutations were assumed to have been acquired since 
the common, ancestral acquisition of the shared mutation.  
 
 
Supplementary Tables: 
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Supplementary Table S1. Bacterial isolates used in this study.  ST refers to the 
designated multilocus sequence type.  *novel shared MLST and they cluster according to 
SNP phylogeny.  Isolates C21-C23 cluster together according to core genome SNP 
phylogeny. Isolates included in the subset of 99 genomes are highlighted in red.  The Mutator 
column indicates the presence of mutations associated with hypermutability (INDEL, causing 
a frameshift or STOP, introduction of a stop codon). Of the 11 isolates carrying such a 
mutation, all but two (B113 and C78) were confirmed as having a hypermutable phenotype 
using assays reported previously [13]. Isolates labelled with the same letter from 
a
 to 
i 
were 
considered to be from the same lineage as each other on the basis of incomplete MLST 
profiles (see Table S2) and clustering by core genome SNP phylogeny (see Figure S1).  
Isolate 
ID 
Center Date Patient ST 
Mutator 
A1 1 09/10/2014 1 17  
A2 1 16/10/2014 2 207  
A3 1 10/10/2014 3 252  
A4 1 10/10/2014 3 252  
A5 1 10/10/2014 3 252  
B3 12 01/11/2008 8 281  
B16 12 25/11/2013 9 253  
B34 12 03/09/2014 11 179  
B37 12 18/01/2012 12 -  
B62 12 03/09/2014 15 -  
B113 12 23/10/2014 18 1328 mutL (INDEL) 
B114 12 11/04/2012 19 198  
B199 12 18/10/2011 32 1182  
A12 1 14/11/2014 35 179  
C2 4 14/10/2009 36 253  
C3 4 25/02/2010 37 260  
C4 4 25/02/2010 37 -
a
  
C5 4 25/02/2010 37 260
 a
  
C6 4 03/03/2010 38 244  
C7 4 23/03/2010 39 244  
C10 4 16/04/2010 40 244  
C8 4 16/04/2010 40 244  
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C9 4 16/04/2010 40 244  
C11 4 19/08/2010 41 282  
C12 4 20/08/2010 42 282  
C13 4 20/08/2010 42 27
 b
  
C14 4 20/08/2010 42 27
 b
  
C15 4 20/08/2010 42 27
 b
  
C16 4 20/08/2010 42 -
b
  
C17 4 20/08/2010 42 -
 b
  
C18 4 15/04/2011 43 - mutL (STOP) 
C20 4 01/07/2011 44 878  
C21 15 14/04/2009 45 -
c
  
C22 15 14/04/2009 45 -
 c
  
C23 15 14/04/2009 45 -
 c
  
C25 15 20/05/2009 46 253  
C29 15 03/06/2009 48 252  
C30 15 04/06/2009 49 252  
C31 15 25/08/2009 50 -
 d
 mutL (INDEL) 
C32 15 25/08/2009 50 -
d
  
C33 15 25/08/2009 50 -
 d
  
C36 15 21/05/2010 52 253  
C42 15 12/07/2010 54 309  
C43 15 28/07/2010 55 108  
C44 15 28/07/2010 55 108  
C45 15 28/07/2010 55 108  
C49 15 22/02/2011 58 395  
C51 15 23/02/2011 59 683  
C54 15 15/06/2011 61 1342  
C55 5 26/06/2009 62 -
 e
  
C56 5 26/06/2009 62 -
e
  
C57 5 26/06/2009 62 -
 e
  
C58 5 26/06/2009 62 -
 e
  
C59 5 26/06/2009 62 -
 e
  
C60 5 26/06/2009 62 -
 e
  
C61 5 17/11/2009 63 620  
C63 3 02/09/2009 64 27  
C64 3 25/11/2009 65 274  
C65 3 25/11/2009 65 274  
C66 3 25/11/2009 65 274  
C67 3 25/11/2009 65 274  
C68 3 25/11/2009 65 274  
C69 3 12/05/2010 66 -  
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C71 9 04/09/2009 67 968  
C73 9 05/11/2010 68 17  
C74 9 03/12/2010 69 1202 mutL (STOP) 
C76 2 12/05/2009 70 253  
C77 2 03/07/2009 71 308  
C78 2 14/07/2009 72 840 mutL (INDEL) 
C79 2 14/07/2009 72 620
 f
 mutL (STOP) 
C80 2 14/07/2009 72 620
 f
  
C81 2 14/07/2009 72 620
 f
  
C82 2 14/07/2009 72 620
 f
  
C83 2 14/07/2009 72 -
f
  
C84 2 14/07/2009 72 620
 f
  
C85 2 06/08/2009 73 -
g
  
C86 2 06/08/2009 73 308  
C87 2 06/08/2009 73 179
 g
  
C88 2 15/12/2009 74 1251  
C89 2 25/03/2010 75 1239  
C91 2 13/01/2011 76 253  
C92 2 01/02/2011 77 252  
C94 10 03/07/2009 78 395  
C95 10 29/07/2009 79 253  
C96 10 29/07/2009 79 253  
C97 10 29/07/2009 79 253  
C98 10 29/07/2009 79 253  
C99 10 29/07/2009 79 253  
C100 10 13/10/2009 80 612  
C101 10 21/10/2009 81 -
 h
  
C102 10 21/10/2009 81 -
h
  
C103 10 21/10/2009 81 -
 h
  
C104 13 16/05/2009 82 179  
C105 13 25/07/2009 83 840  
C106 13 11/08/2009 84 -
i
  
C107 13 11/08/2009 84 253  
C108 13 11/08/2009 84 179
 i
  
C109 13 11/08/2009 85 840  
C110 13 11/08/2009 85 179  
C111 13 11/08/2009 85 179  
C112 13 11/08/2009 85 179  
C114 13 05/12/2009 86 179  
C115 13 05/12/2009 86 179  
C116 13 04/06/2010 87 871  
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C117 13 04/06/2010 87 871  
C118 13 04/06/2010 87 871  
C119 7 23/01/2010 88 -  
C120 7 29/01/2010 89 -  
C123 7 02/04/2010 90 27 mutS (INDEL) 
C124 7 08/04/2010 91 1753  
C125 7 29/04/2010 92 253  
C126 7 29/04/2010 92 253  
C127 7 29/04/2010 92 164 mutS (INDEL) 
C128 7 29/04/2010 92 164  
C129 7 29/04/2010 92 871 mutL (INDEL) 
C131 7 08/05/2010 93 253  
C133 7 28/05/2010 94 253 mutS (INDEL) 
C134 7 19/12/2010 95 253 mutS (INDEL) 
C135 14 02/11/2009 96 160  
C137 14 16/04/2010 97 260  
C139 14 08/09/2010 98 2102  
C141 14 01/10/2010 99 2102  
C142 14 11/02/2011 100 252  
C143 8 08/07/2010 101 253  
C144 8 08/07/2010 101 253  
C145 8 08/07/2010 101 253  
C146 8 25/06/2010 102 395  
C147 8 25/06/2010 102 395  
C148 8 25/06/2010 102 395  
C149 8 22/03/2011 103 108  
C150 6 27/08/2010 104 253  
C151 6 03/03/2011 105 1244  
C153 6 07/04/2011 106 155  
C155 11 04/12/2010 107 1211  
C156 16 16/11/2010 108 260  
C158 16 03/12/2010 109 155  
C159 16 09/12/2010 110 260  
C160 16 09/12/2010 111 1244  
C161 16 03/03/2011 112 110  
C164 16 08/12/2010 113 -  
C167 16 21/04/2011 114 296  
C168 16 21/12/2010 115 17  
A19 1 16/12/2014 120 -  
A163 1 19/05/2015 137 146  
A36 1 17/02/2015 137 146  
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A46 1 07/04/2015 147 17  
A48 1 07/04/2015 147 17  
A52 1 07/04/2015 147 17  
A53 1 07/04/2015 147 17  
A54 1 07/04/2015 147 17  
A55 1 07/04/2015 147 17  
A56 1 07/04/2015 147 17  
A58 1 07/04/2015 147 17  
A60 1 07/04/2015 147 17  
A70 1 07/04/2015 147 17  
A71 1 07/04/2015 147 17  
A72 1 07/04/2015 147 17  
A73 1 07/04/2015 147 17  
A75 1 07/04/2015 147 17  
A76 1 07/04/2015 147 17  
A100 1 07/04/2015 148 17  
A106 1 07/04/2015 148 175  
A107 1 07/04/2015 148 175  
A77 1 07/04/2015 148 175  
A78 1 07/04/2015 148 17  
A80 1 07/04/2015 148 175  
A81 1 07/04/2015 148 17  
A82 1 07/04/2015 148 17  
A85 1 07/04/2015 148 175  
A86 1 07/04/2015 148 175  
A90 1 07/04/2015 148 175  
A91 1 07/04/2015 148 175  
A92 1 07/04/2015 148 175  
A95 1 07/04/2015 148 175  
A97 1 07/04/2015 148 175  
A119 1 15/05/2015 149 667  
A122 1 15/05/2015 149 667  
A123 1 15/05/2015 149 667  
A126 1 15/05/2015 149 667  
A130 1 15/05/2015 149 667  
A134 1 15/05/2015 149 667  
A137 1 15/05/2015 149 667  
A141 1 15/05/2015 149 667  
A144 1 15/05/2015 149 667  
A147 1 15/05/2015 149 667  
A148 1 15/05/2015 149 667  
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A151 1 15/05/2015 149 667  
A154 1 15/05/2015 149 667  
A156 1 15/05/2015 149 667  
      
 
 
Supplementary Table S2.  MLST profiles of isolates where incomplete profiles were 
obtained or the MLST profile was novel. 
Isolate ST Closest ST 
Pseudomonas aeruginosa MLST 
loci allele numbers 
acs aro gua mut nuo pps trp 
A19 NF 92 or 261 105 5 30 - 1 4 14 
B37 Novel 107 4 3 27 12 7 128 
B62 NF 1404 16 - 6 3 4 7 1 
C101 NF 303 (4 loci) 16 - 12 18 3 4 9 
C102 NF 304 (4 loci) 16 - 12 18 3 4 9 
C103 NF 305 (4 loci) 16 - 12 18 3 4 9 
C106 NF 156,179,353,1494 (6 loci) - 27 28 3 4 13 7 
C119 Novel 5 1 109 3 1 1 47 
C120 Novel 17 5 11 5 4 29 2 
C164 NF 1240,1985 (4 loci) 28 5 46 5 1 - 61 
C16 NF 27,120,2314 (5 loci) 6 - 6 113 4 6 7 
C17 NF 27,120,2314 (5 loci) 6 - 6 113 4 6 7 
C18 NF 
158,179,180,1496,2063,2109 (6 
loci) 36 27 28 - 4 13 7 
C21 Novel 22 6 1 3 1 76 1 
C22 Novel 22 6 1 3 1 76 1 
C23 Novel 22 6 1 3 1 76 1 
C31 NF 155,677,1276 (5 loci) 28 5 36 - 3 13 7 
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C32 NF 155,677,1276 (5 loci) 28 5 36 - 3 13 7 
C33 NF 155,677,1276 (5 loci) 28 5 36 - 3 13 7 
C4 NF 260 (6 loci) 14 5 - 7 4 13 7 
C55 Novel 28 5 11 11 15 75 1 
C56 Novel 28 5 11 11 15 75 1 
C57 Novel 28 5 11 11 15 75 1 
C58 Novel 28 5 11 11 15 75 1 
C59 Novel 28 5 11 11 15 75 1 
C60 Novel 28 5 11 11 15 75 1 
C69 NF 1707, 2055 (6 loci) 16 24 1 149 4 - 19 
C83 NF 620 (6 loci) 9 7 63 13 8 - 8 
C85 NF 156, 179, 353, 1494 (6 loci) - 27 28 3 4 13 7 
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Table S3. Clonal lineages isolated from multiple patients within individual centres.   Sets 
of isolates from different patients attending the same centre are grouped by clonal lineage. 
For each such group, whole genome pairwise comparisons were carried out to determine the 
number of variant SNPs and INDELs.  *These isolates share a novel MLST profile and they 
cluster according to SNP phylogeny.   
 
 
Isolate Centre Isolation date Patient MLST Comparison SNPs INDELs 
C6 4 03/03/2010 38 244 
     C6-C7 
C6-C8 
C6-C9 
C6-C10 
C7-C8 
C7-C9 
C8-C9 
C7-C10 
C8-C10 
C9-C10 
      179 
3790 
3733 
3833 
3736 
3714 
281 
3929 
603 
515 
        8 
       79 
       74 
62 
82 
75 
5 
65 
14 
11 
C7 4 23/03/2010 39 244 
C8 4 16/04/2010 40 244 
C9 4 16/04/2010 40 244 
C10 4 16/04/2010 40 244 
        
C11 4 19/08/2010 41 282 C11-C12 340 8 
C12 4 20/08/2010 42 282    
        
C29 15 03/06/2009 48 252 C29-C30 168 3 
C30 15 04/06/2009 49 252    
C25 15 20/05/2009 46 253 C25-C36 3428 43 
C36 15 21/05/2010 52 253    
C91 2 13/01/2011 76 253 C76-C91 846 5 
C76 2 12/05/2009 70 253    
        
C77 2 03/07/2009 71 308 C77-C86 277 1 
C86 2 06/08/2009 73 308    
C105 13 25/07/2009 83 840 C105-C109 131 8 
        
C109 13 11/08/2009 85 840    
C104 13 16/05/2009 82 179 
C104-C108 
C104-C110 
C104-C111 
C104-C112 
C104-C114 
C104-C115 
C108-C110 
C108-C111 
C108-C112 
10,551 
2863 
2765 
1913 
6795 
6972 
4780 
4852 
3780 
114 
39 
52 
25 
96 
105 
78 
66 
62 
C108 13 11/08/2009 84 179 
C110 13 11/08/2009 85 179 
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C111 13 11/08/2009 85 179 
C108-C114 
C108-C115 
C110-C111 
C110-C112 
C110-C114 
C110-C115 
C111-C112 
C111-C114 
C111-C115 
C112-C114 
C112-C115 
C114-C115 
 
10,963 
10,833 
176 
198 
3115 
3107 
148 
2838 
2789 
1941 
1895 
281 
136 
133 
8 
7 
40 
45 
4 
43 
57 
29 
31 
4 
C112 13 11/08/2009 85 179 
C114 13 05/12/2009 86 179 
C115 13 05/12/2009 86 179 
        
C125 7 29/04/2010 92 253 C125-C126 
C125-C131 
C125-C133 
C125-C134 
C126-C131 
C126-C133 
C126-C134 
C131-C133 
C131-C134 
C133-C134 
736 
1159 
872 
817 
9636 
5847 
5883 
3486 
3400 
330 
27 
22 
22 
21 
99 
71 
70 
40 
38 
4 
C126 7 29/04/2010 92 253 
C131 7 08/05/2010 93 253 
C133 7 28/05/2010 94 253 
C134 7 19/12/2010 95 253 
        
C156 16 16/11/2010 108 260 C156-C159 160 3 
C159 16 09/12/2010 110 260 
        
C139 14 08/09/2010 98 ST2102 C139-C141 177 3 
C141 14 01/10/2010 99 ST2102 
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Supplementary Table S4 and Figure S1 are provided in additional files: 
Table S4. Clone-specific deletions, relative to PAO1 
Figure S1.  Core genome SNP phylogeny showing the distribution of bronchiectasis isolates.  
The figure shows analysis of the genomes of all bronchiectasis isolates used in this study 
(highlighted in blue) alongside 331 genomes from Kos et al. [14] and the genomes of 
commonly studied strains PAO1 (labelled PAO1107), PA14 (UCBPPPA14109), PA7 and 
LESB58.  Line colours indicate the two major clusters of P. aeruginosa (I, green; II, blue) as 
well as those isolates not clustering in the two main groups (red). 
Figure S2. Distribution of loss of function mutations.  For the genes listed in Table 2, where 
the number of independent occurrences of a loss of function mutation was equal to or greater 
than five, the Figure indicates the number of isolates carrying mutations in 0, 1, 2, 3, 4, 5 or 6 
of these genes. 
 
 
Table S5. Full list of loss of function mutations identified by variant calling.  Available via 
the Figshare link https://figshare.com/s/ff426bae75ee64804aa1 
Table S6. Loss of function mutations present in each bronchiectasis isolate genome.  For the 
genes listed in Table 2, where the number of independent occurrences of a loss of function mutation 
was equal to or greater than five, the genes carrying such mutations are shown for each of the 
bronchiectasis isolates.  17 of the 99 isolates carried none of these mutations.  It is worth noting that 
isolates found co-infecting individual patients did not share the same mutation profile (C125, C127 
0
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and C129 in patient 92; C12 and C13 in patient 42; C78 and C79 in patient 72; C86 and C87 in patient 
73; C107 and C108 in patient 84; C109 and C110 in patient 85; A100 and A106 in patient 148). 
Isolate 
Number 
of Table2 
genes 
with loss 
of 
function 
mutations Mutations 
C125 6 PA4469  mexS  ladS  rbdA  betT2  mexA 
C74 6 PA4469  mexS  chpA  mutL  pchE  mexB 
C87 6 PA4469  bifA  pchE  ladS  chpA  mexA 
C123 5 rbdA  PA4469  pchE  mexS  oprM 
 C116 5 PA4469  mucA  mexB  oprF  pchE 
 C88 5 mucA  pcoA  betT2  oprF  mexA 
 C100 4 rbdA  PA4469  mucA  chpA 
 C79 4 rbdA  PA4469  mucA  mutL 
 C133 4 rbdA  mucA  pchE  oprM 
 C95 4 rbdA  mucA  oprM  pcoA 
 B16 4 rbdA  mucA  mexB  fimV 
 C21 4 PA4469  mucA  mexB  pcoA 
 C31 4 PA4469  mucA  mutL  fimV 
 C110 4 PA4469  mucA  oprF  mexA 
 C108 4 mexB  chpA  mucA  betT2 
 C129 4 mucA  mexB  oprF  gmd 
 C134 3 rbdA  mucA  oprM 
 C143 3 rbdA  mucA  mexB 
 C2 3 rbdA  mexB  chpA 
 A119 3 PA4469  oprF  pcoA 
 A46 3 PA4469  mucA  oprF 
 C63 3 betT2  ladS  fimV 
 C114 3 mexB  pchE  betT2 
 A163 3 mucA  mexB  gmd 
 C149 3 mucA  pchE  oprM 
 C55 3 mucA  pilJ  oprF 
 B113 3 pilJ  mutL  pcoA 
 C124 2 PA0054  mucA 
 C146 2 PA0054  mexA 
 C49 2 PA0054  betT2 
 C51 2 PA0054  rbdA 
 B114 2 rbdA  mexB 
 C25 2 rbdA  mexB 
 C36 2 rbdA  mucA 
 C86 2 rbdA  mexA 
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C20 2 rbdA  pilJ 
    C137 2 rbdA  PA4469 
 C6 2 PA4469  mexS 
    C7 2 PA4469  mexS 
 C135 2 mucA  mexS 
    C61 2 PA4469  mexA 
 C42 2 PA4469  oprF 
    A100 2 PA4469  fimV 
 B62 2 PA4469  pilJ 
    C131 2 betT2  ladS 
 B34 2 bifA  betT2 
    C12 2 bifA  betT2 
 C11 2 bifA  betT2 
    A1 2 bifA  ladS 
 B3 2 fimV  pcoA 
    C167 2 mexA  gmd 
 C3 2 pilJ  mexB 
    A2 2 mucA  mexB 
 C153 2 mexB  oprF 
    C158 2 mexB  oprF 
 C161 2 mucA  pcoA 
    C18 2 oprM  mutL 
 C155 2 pilJ  oprM 
    C94 1 PA0054 
 C120 1 rbdA 
     A3 1 rbdA 
 C77 1 rbdA 
     C91 1 rbdA 
 C69 1 rbdA 
     C156 1 rbdA 
 C159 1 rbdA 
     C107 1 betT2 
 C119 1 bifA 
     A106 1 bifA 
 C43 1 bifA 
     B199 1 gmd 
 C89 1 gmd 
     C168 1 gmd 
 A12 1 mexB 
     C54 1 mexB 
 C92 1 mucA 
     C10 1 mucA 
 C73 1 mucA 
     C142 1 mucA 
 C76 1 mucA 
     B37 1 mucA 
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C101 1 oprM 
      
Table S7.  The presence or absence of virulence genes amongst the non-CF BE isolate 
genomes.  Available via the Figshare link https://figshare.com/s/626a59cfd94b13e5cf71 
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Table S4. Clone-specific deletions relative to PAO1.
Isolate* Deleted DNA† Size of Deleted Genes‡
From To deletion (bp)From To
A12 2448472 2723305 274833 PA2226 PA2427
A119 2443094 2624360 181189 PA2221 PA2373
A119 5455322 5497400 42078 PA4857 PA4900
A163 2543016 2705463 162447 PA2305 PA2421
A19 2420900 2721500 300600 PA2201 PA2425
A78 2439040 2574546 135506 PA2218 PA2333
B34 1979190 2015165 35975 PA1820 PA1856
B62 2461847 2686720 224873 PA2237 PA2402
C100 2443095 2724005 280910 PA2221 PA2428
C101 2452047 2578374 126327 PA2229 PA2335
C119 2184340 2247131 62791 PA1997 PA2053
C119 2487183 2689945 202762 PA2258 PA2406
C125 2439064 2729482 290418 PA2218 PA2432
C135 2443095 2588618 145523 PA2221 PA2343
C137 2453340 2560360 107020 PA2231 PA2321
C155 2440000 2585490 145490 PA2218 PA2431
C156 2439060 2475845 36785 PA2218 PA2249
C164 2248926 2451500 202574 PA2055 PA2228
C164 2793790 2810695 16905 PA2475 PA2494
C164 3914150 3930740 16590 PA3497 PA3514
C21 2439057 2713422 274365 PA2218 PA2424
C22 2209250 2442066 232816 PA2018 PA2220
C4 111095 211425 100330 PA0091 PA0781
C4 2439055 2666000 226945 PA2218 PA2400
C44 2443095 2615075 171980 PA2221 PA2365
C5 3841807 3873962 32155 PA3434 PA3463
C51 2071372 2199654 128282 PA1900 PA2010
C54 762796 789380 26584 PA0691 PA0717
C54 2410960 2478550 67590 PA2191 PA2251
C54 2628400 2817536 189136 PA2377 PA2500
C61 4005650 4016519 10869 PA3573 PA3584
C6 2448920 2689471 240551 PA2227 PA2405
C73 2460955 2584136 123181 PA2236 PA2399
C87 2461666 2606428 144762 PA2237 PA2359
C87 2787221 2828217 40996 PA2469 PA2511
C96 2705835 2863924 158089 PA2422 PA2535
*For identical strains with the same deletion, only one strain is listed
†Coordinates of P. aeruginosa PAO1
‡P. aeruginosa strain PAO1 locus ID
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Abstract  1 
To characterise Pseudomonas aeruginosa populations during chronic lung infections of non-2 
Cystic Fibrosis bronchiectasis patients, we used whole genome sequencing to (i) assess the 3 
diversity of P. aeruginosa and the prevalence of multi-lineage infections, (ii) seek evidence 4 
for cross-infection or common source acquisition and (iii) characterize P. aeruginosa 5 
adaptations. 6 
189 isolates, obtained from the sputa of 91 patients attending 16 adult UK 7 
bronchiectasis centres, were whole genome sequenced. 8 
Bronchiectasis isolates were representative of the wider P. aeruginosa population.  Of 9 
24 patients where multiple isolates were examined, there were seven examples of multi-10 
lineage infections, most likely arising from multiple infection events. The number of 11 
nucleotide variants between genomes of isolates from different patients was in some cases 12 
similar to the variations observed between isolates from individual patients implying the 13 
possible occurrence of cross infection or common source acquisition.  14 
Our data indicate that during infections of bronchiectasis patients, P. aeruginosa 15 
populations adapt by accumulating loss of function mutations, leading to changes in 16 
phenotypes including different modes of iron acquisition and variations in biofilm-associated 17 
polysaccharides. The within-population diversification suggests that larger scale longitudinal 18 
surveillance studies will be required to capture cross infection or common source acquisition 19 
events at an early stage. 20 
 21 
Abstract word count: 196  22 
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Introduction 23 
Bronchiectasis is a chronic, progressive respiratory disease associated with irreversible 24 
widening of the bronchi [1].  Recent data suggest that in the UK incidence rates in women 25 
and men have risen to 35.2 and 26.9 respectively per 100,000 person-years [2].  In the USA 26 
the prevalence of adult bronchiectasis has been estimated at 52 in 100 000 people, with 27 
higher prevalence among women and older individuals [3].  Persistent Pseudomonas 28 
aeruginosa lung infections of bronchiectasis patients, occuring in approximately 30% of 29 
cases, are associated with poorer outcomes and premature mortality [4, 5]. 30 
The study of chronic P. aeruginosa lung infections has focused on cystic fibrosis 31 
(CF)-associated bronchiectasis, where patients are diagnosed, monitored and subjected to 32 
antibiotic therapy from a very early age. This contrasts with non-CF bronchiectasis patients, 33 
who present at a much older age and often have a shorter history of therapeutic interventions. 34 
Hence, bacterial isolates from non-CF bronchiectasis patients exhibit less resistance to 35 
antibiotics compared to isolates from adult CF patients [6]. Previous studies have 36 
characterized the evolution of P. aeruginosa during chronic lung infections in CF patients [7, 37 
8].  More recently, high-resolution analyses have revealed extensive heterogeneity within P. 38 
aeruginosa populations in the CF lung [9-12], including the co-existence of multiple 39 
divergent lineages [13].   40 
In CF, a number of transmissible strains of P. aeruginosa have been identified, 41 
leading to the introduction of measures to control cross infection [14]. The study of P. 42 
aeruginosa in relation to non-CF bronchiectasis is less advanced.  In our single centre study 43 
of 50 P. aeruginosa isolates from 40 bronchiectasis patients using molecular typing, there 44 
was no compelling evidence for cross infection or a dominant clone [15].  However, whole 45 
genome sequence analysis of multiple bronchiectasis isolates has not been carried out. Here, 46 
we report the use of genomics to assess the diversity of P. aeruginosa strains causing 47 
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infections in non-CF bronchiectasis across multiple UK centres, to identify multi-strain 48 
infections, and to look for evidence for cross-infection or common source acquisition.  We 49 
also characterise adaptive mutations and present evidence for within-population divergence 50 
during P. aeruginosa chronic lung infections of bronchiectasis patients.  51 
 52 
Methods 53 
Patients and bacterial isolates 54 
The 189 P. aeruginosa isolates used in this study (see Table S1 in the online supplementary 55 
material) were isolated from sputum samples obtained from 93 patients with bronchiectasis 56 
and chronic P. aeruginosa infection (defined as two or more positive respiratory tract cultures 57 
in the preceding 12 months) attending 16 adult bronchiectasis centres throughout England 58 
and Wales. These included isolates collected as part of a multi-centre nebulized antibiotic 59 
trial [16], where patients were enrolled within 21 days of completing a course of 60 
antipseudomonal antibiotics for an exacerbation. Additional isolates from Newcastle (n = 8) 61 
and Liverpool (n = 53) were collected during observational studies.  The methodology used 62 
for isolating P. aeruginosa from patient sputum samples is described in the online 63 
supplementary material.  64 
For 24 patients, sets of isolates (two or more) from the same sample were analysed to 65 
look for evidence of multi-lineage infections.  For three of these patients (patients 147 – 149), 66 
sets of 14 or 15 isolates from a single sample were sequenced for higher resolution analysis 67 
of within-population heterogeneity. For some analyses, to avoid biases arising from inclusion 68 
of multiple clonal genomes from the same patient, a subset of 99 genomes from 91 patients 69 
was used. This subset consisted of one randomly selected genome per clonal lineage per 70 
patient (see Table S1 in the online supplementary material).  We use the term “clonal 71 
lineage” to describe isolates with shared multilocus sequence type (MLST) profile and 72 
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clustering according to core genome single nucleotide polymorphism (SNP)-based 73 
phylogeny. 74 
 75 
DNA preparation and whole genome sequencing  76 
Details of the extraction of genomic DNA from P. aeruginosa isolates, library preparation 77 
and whole-genome shotgun sequencing using Illumina short read sequencing technology are 78 
given in the online supplementary material. The European Nucleotide Archive accession 79 
number for the study is PRJEB14952. 80 
Methods used for genome sequence assembly, extraction of MLST data, phylogenetic 81 
reconstruction using the core genome, and variant calling by mapping to the genome of 82 
PAO1 [17] to identify single nucleotide polymorphism (SNP) or small insertions or deletions 83 
(INDELs) are described in online supplementary material.   84 
 85 
Identification of large deletions and virulence factor genes 86 
Genome sequences were aligned to the reference genomes P. aeruginosa PAO1 87 
(NC_002516, [17]) and P. aeruginosa LESB58 (FM209186; [18]) and large clone-specific 88 
deletions (10 kb and above) were identified using BRIG [19]. The boundaries of deletions 89 
were determined by aligning the genome sequences with the P. aeruginosa PAO1 genome 90 
using Mauve [20], implemented as part of the Geneious package (www.geneious.com). The 91 
presence and absence of virulence factor genes in genome assemblies was determined using 92 
Blastable (https://www.github.com/bawee/blastable). The Pseudomonas genome database 93 
(beta.pseudomonas.com) [21] was used to facilitate analysis of gene function.  94 
 95 
Results 96 
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Diversity of P. aeruginosa Non-CF BE isolates and evidence for P. aeruginosa multi-97 
lineage co-infections 98 
Core genome SNP phylogenetic analysis alongside a collection of 331 P. aeruginosa isolate 99 
genomes from diverse clinical sources [22], indicated that the bronchiectasis isolates were 100 
widely distributed (see Figure S1 in the online supplementary material). From the 189 101 
isolates, it was possible to extract complete MLST profiles for 160 (see Tables S1 and S2 in 102 
the online supplementary material), with the most widespread sequence types (STs) being 103 
ST-253 (PA14-like [23], 14 patients, 8 centres), ST-179 (7 patients, 4 centres), ST-17 (Clone 104 
C [23], 5 patients, 3 centres), ST-252 (4 patients, 4 centres) and ST-260 (4 patients, 3 105 
centres).  Using core genome SNP phylogeny, previous studies have sub-divided the wider P. 106 
aeruginosa population into two major groups (group I, which includes strain PAO1, and 107 
group II, which includes strain PA14) and one minor group of mostly unrelated clonal 108 
lineages [24, 25].  Of a subset of 99 genomes consisting of one randomly selected genome 109 
per clonal lineage per patient, 71 were located in group I and 27 in group II (Figure 1).  Based 110 
on a combination of MLST genotype and core genome SNP phylogeny, of the 24 patients 111 
from whose samples multiple isolates were examined, there were seven examples of multi-112 
lineage infections.  In one patient (patient 92), three distinct clonal lineages of P. aeruginosa 113 
were identified.  In patients 42, 72, 73, 84, 85 and 148 there were two co-existing lineages 114 
(Figure 1).   115 
 116 
Evidence for shared lineages causing infections in different patients attending the same 117 
centre 118 
The core genome SNP phylogeny identified a number of examples where closely-related 119 
clonal lineages were isolated from more than one patient attending the same centre (see Table 120 
S3 in the online supplementary material).  In order to obtain a higher resolution comparison, 121 
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these isolates were analysed using pairwise comparisons across their entire genomes (Table 122 
S3), identifying five instances where the genomes of isolates from different patients attending 123 
the same centre varied at fewer than 200 sites (C6/C7, C29/C30, C105/109, C139/C141, 124 
C156/C159; Figure 2).  This level of genome similarity is greater than in some pairwise 125 
comparisons of contemporary isolates of the same lineage from the same sputum sample (see 126 
Table S3 in the online supplementary material; from 184 variant sites [C110/C111] to >750 127 
variant sites [C125/C126]). 128 
The draft genome sequences of the sub-set of 99 bronchiectasis isolates were 129 
examined for the presence of large (> 10kb) deletions. A total of 36 different deletions (25 130 
over 100 kb), ranging in size from 11 to 300 kb and representing independent genetic events, 131 
were identified (see Table S4 in the online supplementary material). These were distributed 132 
across 28 genomes in the 99-member genome subset. Most genomes had only one deletion, 133 
although two (C54 and C164) had three deletions and four (A119, C4, C85 and C119) had 134 
two. In most cases, isolates of the same clonal lineages from the same patient shared the same 135 
deletions. However, in patients 45, 55, 79 and 92 not all isolates of the same lineage had the 136 
same deletion.  The genomes of isolate pairs C6/C7, C29/C30, C105/109, C139/C141 and 137 
C156/C159, which are from different patients but vary at fewer than 200 sites (Table 1), were 138 
indistinguishable by BRIG analysis (example shown in Fig. 3B).  139 
 140 
Genomic diversity of isolates within patients can be similar to diversity between patients 141 
In order to further assess the within-patient diversification exhibited by P. aeruginosa 142 
populations, larger sets of isolates from single sputum samples were analysed for three 143 
patients : 147 (15 isolates), 148 (15 isolates) and 149 (14 isolates) (Table 1). For two of these 144 
patients, the P. aeruginosa population was comprised of a single clonal lineage.  For patient 145 
148, two distinct clonal lineages were identified and these two sets of isolates were analysed 146 
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separately.  In all four isolate sets analysed, the maximum pairwise SNP variations between 147 
two isolates of the same lineage exceeded 300, with a median of 179 or greater (Table 1), 148 
indicating the occurrence of within-patient diversification. 149 
  150 
Loss of function mutations and deletions identified in multiple isolates 151 
We used variant calling approaches to identify independent occurrences of loss of function 152 
mutations amongst the sub-set of 99 bronchiectasis isolate genomes.  This yielded a number 153 
of examples of genes with known functions carrying independent loss of function mutations 154 
in multiple isolates (Table 2; see Table S5 in the online supplementary material).  These 155 
include genes linked to mucoidy, virulence, osmoprotection, biofilm formation, motility, 156 
DNA repair and antimicrobial resistance (Table 2).  The genes encoding all three components 157 
of the MexAB-OprM efflux pump appear amongst the most common loss of function 158 
mutations.  Multiple isolates also carried loss of function mutations in genes encoding 159 
regulators (including lasR, algU, fleR, vfr).  Among the 99 bronchiectasis isolates, the 160 
number of genes with loss of function mutations as listed in Table 2 ranged from 0 to 6 (see 161 
Figure S2 and Table S6 in the online supplementary material). 162 
 163 
Hypermutability is a common trait amongst CF isolates of P. aeruginosa.  Of the 99 164 
panel isolates, 11 carried loss of function mutations in the DNA mismatch repair genes, mutS 165 
or mutL (see Table S1 in the online supplementary material).  All but two of these were 166 
confirmed as having the hypermutable phenotype. 167 
  An alignment of all of the genomes containing deletions >10 kb relative to the 168 
genome of strain PAO1 revealed a strikingly non-random distribution, with 30 of the 36 169 
deletions lying within the 1.9 to 2.8 Mb portion of the strain PAO1 genome. Genes within 170 
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this region include the psl genes, encoding an extracellular polysaccharide [26], genes 171 
encoding the siderophore pyoverdine, and genes encoding a type VI secretion apparatus [27]. 172 
 173 
We next specifically examined one representative of each of the 99 clonal lineages for 174 
the presence or absence of genes associated with pathogenicity (see Table S6 in the online 175 
supplementary material).  23 of these genomes lacked one or more of the psl genes. In 176 
contrast, all of the genomes contained all of the alg genes required for making alginate and 177 
the pel genes required for making Pel exopolysaccharide.  Eleven of the genomes lacked 178 
genes required for synthesis of pyoverdine, with nine of these also lacking an fpvA receptor 179 
gene for uptake of ferripyoverdine, although the genes required for synthesis of an alternative 180 
siderophore, pyochelin, were present in all cases. Eleven of the genomes also lacked two or 181 
more genes of the Type VI secretion system [PA2360 (hsiA3) – PA2373 (vgrG3)] (see Table 182 
S6 in the online supplementary material). These findings are consistent with the occurrence 183 
of deletions of the region of the genome containing Psl, pyoverdine and type VI secretion 184 
genes in multiple isolates, although in some isolates smaller deletions (< 10kb) were detected.  185 
 186 
Discussion 187 
We used whole genome sequencing to obtain a cross section of the diversity of P. aeruginosa 188 
strains causing infections in bronchiectasis in the UK.  Our data suggest that the distribution 189 
of P. aeruginosa lineages found amongst the bronchiectasis isolate collection broadly 190 
represents what is present in the global P. aeruginosa population.  In contrast to CF [14], we 191 
found no data to suggest that there is a widespread transmissible strain amongst the UK non-192 
CF bronchiectasis community.  However, our study did not include large numbers of patients 193 
from individual centres.  Lineages such as PA14-like and Clone C, that are naturally more 194 
abundant in nature [23], were also amongst the most abundant in the bronchiectasis 195 
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collection.  Because some lineages are naturally more abundant, their occurrence (based on 196 
MLST) in multiple patients is not necessarily indicative of common source or cross infection.  197 
Whole genome sequencing offers higher resolution than methods such as MLST, allowing us 198 
to address this issue. 199 
In a previous comparison of paired isolates from patients within the same 200 
bronchiectasis centre, in most patients (9 of 10) the two isolates shared a common genotype, 201 
with one patient found to be infected with two strains simultaneously [15].   In this study, of 202 
24 patients from whose samples multiple isolates were examined, seven had multi-lineage 203 
infections.   Similar multi-lineage infections have also been reported in CF, generally 204 
associated with children [28].  A number of studies in CF have also demonstrated the 205 
phenotypic [9, 11, 12] and genomic [10, 13, 29] diversification of single lineage P. 206 
aeruginosa populations in the CF lung.  Here, we show for the first time that similar 207 
diversification occurs during infections of non-CF bronchiectasis patients.  Both the 208 
prevalence of multi-lineage infections, and the diversification that occurs during the infection 209 
process emphasise the need to be cautious when interpreting the analysis of sputum samples 210 
based on single isolates of P. aeruginosa. 211 
We found several examples of isolates from patients attending the same centre, that 212 
not only shared the same clonal lineage, but also differed genomically by <200 sites.  213 
Genomic variations between isolates from the same patient sample revealed similar, and in 214 
some cases higher, levels of variation.  The occurrence of isolates with very high genetic 215 
relatedness in different patients strongly implies that there has been common source 216 
acquisition or cross infection.  The extent of the nucleotide variations differentiating two 217 
isolates will be dependent upon (i) the length of time since the transmission event and (ii) the 218 
rate of mutation of the P. aeruginosa population during the infection.  Further studies will be 219 
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needed to better define the role of cross infection or common source acquisitions in this 220 
patient group. 221 
There was clear evidence for bacterial adaptation to the lung environment by the 222 
accumulation of mutations and deletions, including loss of function mutations in genes 223 
identified previously as being commonly mutated in CF, such as mucA (mucoidy) and lasR 224 
(quorum sensing). It is worth noting, however, that mutations in genes encoding some of the 225 
regulators highlighted in previous CF studies (mexT, retS, exsD, ampR) were observed either 226 
infrequently (two mexT and two ampR mutants) or not at all (see Table S5 in the online 227 
supplementary material).  Mutations in global regulators potentially affect numerous 228 
processes. In CF, the pathoadaptive genes identified in different studies have varied, 229 
suggesting that there are multiple routes to adaptation to the CF lung [7, 8], a scenario which 230 
is likely to apply also to non-CF bronchiectasis. 231 
Loss of function mutations in genes encoding the MexAB-OprM efflux pump were 232 
common amongst the bronchiectasis isolates.  Although generally thought of as a multidrug 233 
efflux system important for antibiotic resistance, this system has also been implicated in 234 
virulence [30]. Hence, although it may seem counterintuitive that P. aeruginosa should adapt 235 
by losing an antibiotic resistance-related efflux pump, it may be that the driver for selection is 236 
related to a function other than antibiotic efflux.  In contrast, the loss of function mutations in 237 
mexS can be linked directly to antibiotic resistance, since mutations in mexS promote 238 
upregulation of the MexEF-OprN MDR efflux pump [31].  239 
The prevalence amongst non-CF BE isolates of deletions in a specific genomic region 240 
encoding pyoverdine and Psl polysaccharide was higher than in a dataset of 331 P. 241 
aeruginosa clinical isolate genomes [22], where 22 genomes lacked one or more psl genes, 242 
only three lacked one or more of the pyoverdine synthesis genes, and only one did not have 243 
an fpvA receptor gene. P. aeruginosa can utilise multiple pathways for iron acquisition [32]. 244 
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During chronic lung infections in CF, P. aeruginosa adapts by favouring the heme utilisation 245 
route for iron acquisition rather than the pyoverdine siderophore system [33].  Our 246 
observations suggest a similar adaptation in non-CF bronchiectasis.  247 
In order to protect itself from hostile environmental conditions or host defences P. 248 
aeruginosa can produce three exopolysaccharides contributing to biofilm formation: alginate, 249 
Psl and Pel [26].  It has been suggested that Psl is a key surface attachment determinant [34], 250 
whereas in the CF lung free-floating biofilm structures may be more important [35]. Other 251 
mutations favouring the production of Pel rather than Psl include mutations in bifA [36], rbdA 252 
[37], oprF [38] and ladS [39].  Hence, overall our observations indicate that in non-CF BE 253 
chronic lung infections, the Pel and alginate exopolysaccharides are favoured over Psl. 254 
Other common loss of function mutations (in pilJ, chpA and fimV) are implicated in 255 
lost or amended twitching motility, an adaptation also seen both in CF [8] and in an artificial 256 
sputum biofilm model [40], suggesting that this may be an adaptation related to the viscosity 257 
of the sputum environment.  258 
Our study represents the first comparative genomics analysis of multiple P. 259 
aeruginosa isolates associated with chronic lung infections of non-CF bronchiectasis patients.  260 
Although a larger, more targeted study, analysing greater numbers of isolates per sample, 261 
would be needed to determine the true prevalence of multi-lineage infections, this 262 
observation does suggest that it is common for multiple P. aeruginosa lineages to co-exist in 263 
bronchiectasis infections.  Our study also demonstrates that within-sample diversity can be 264 
comparable in scale to the genetic variations that occur between isolates from different 265 
patients attending the same centre. These observations suggest that there is an urgent need for 266 
more detailed and larger scale longitudinal studies in non-CF patients, and for surveillance 267 
that captures the diversity within centres and would identify cross infection or common 268 
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source acquisition events earlier, allowing measures to be taken in order to minimise the 269 
spread of this important pathogen. 270 
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 280 
Figure legends. 281 
Figure 1. Evidence for multi-lineage co-infections in seven patients.  The figure shows a 282 
core genome SNP phylogeny for the sub-set of 99 isolates, confirming that all but one isolate 283 
(B113) clusters into one of two major groups. Each bronchiectasis centre is represented by a 284 
different colour.  Arrows sharing the same colour indicate isolates that were obtained from 285 
the same patient.  The three isolates from the same patient 92 sample are numbered 1-3. 286 
 287 
Figure 2. Example pairwise comparisons between isolates sharing the same clonal 288 
lineage that were isolated from more than one patient attending the same centre.  The 289 
number of SNP variations are indicated, with the number of IN-DEL variations shown in 290 
brackets.  Full details are shown in Table S3 in the online supplementary material.  The five 291 
examples where isolates shared fewer than 200 variant sites are highlighted in green.  All 292 
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isolates of ST-244 from patients attending Centre 4 were compared, with similarity graded 293 
according to variant sites (<200, green; 200 – 3000 orange; >3000 red).   294 
 295 
Figure 3. Examples of alignment of genomes of bronchiectasis strains with that of 296 
reference strain P. aeruginosa PAO1. Sequences identified as present (dark grey) or absent 297 
(white) in the genome of PAO1 are indicated. (A) Isolates of the same lineage (ST-253) from 298 
the same patient. From innermost to outermost, C95, C97, C98, C99, C96. A deletion present 299 
in isolate C96 only is highlighted (see arrow). (B) Pairs of isolates (from innermost to 300 
outermost C6 and C7; and C156 and C159) that both share the same clonal lineage but are 301 
from different patients attending the same hospital. Isolates C6 and C7 share a large deletion 302 
and isolates C156 and C159 share a smaller overlapping deletion (Supplementary Table S4), 303 
as indicated (see arrows). (C) Isolates of different lineages from the same patient. From 304 
innermost to outermost, A77, A80, A85 (all ST-175); A78, A81, A82 (all ST-17). A large 305 
deletion present in the ST-17 isolates is indicated by an arrow. The figures were generated 306 
using BRIG. 307 
 308 
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Table 1.  Summary of genomic diversity observed within the same clonal lineage of P. aeruginosa in individual patients 
  
Patient 
Number 
of isolates 
Mean 
SNPs 
Median 
SNPs 
SNP 
range 
Mean 
Indels 
Median 
Indels 
Indel 
range 
Patient 147  15 336.35 261.00 88-640 15.20 14.00 0-35 
Patient 148 (ST17)  4 451.50 482.50 159-654 23.83 25.50 6-34 
Patient 148 (ST175)  11 195.45 179.00 79-403 9.27 5.00 0-36 
Patient 149 14 209.01 206.00 68-327 11.40 10.00 3-28 
 
The table indicates the number of single nucleotide polymorphisms (SNPs) and small insertion and deletion (INDEL) differences between the 
genomes of contemporary isolates from single sputum samples.   
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Table 2 Loss of function mutations occurring in multiple isolates.   Only mutations predicted to lead to loss of function were included (ie. 
introduction of a stop codon, or a frame-shift mutation).  The number of independent mutations indicates the number of isolates carrying unique 
mutations in the listed gene.  The Table shows those genes where the number of independent occurrences of a mutation was equal to or greater 
than five. 
 
Gene PAO1 
gene 
number 
Number of 
independent 
occurrences 
of a 
mutation 
Function / Comment 
mexB PA0426 16 Transporter from MexAB-OprM efflux pump, antibiotic resistance, virulence 
mucA PA0763 13 Anti-sigma factor, mutations can lead to mucoidy.  
betT2  PA5291 9 Transporter, uptake of small molecules such as choline and glycine betaine, contributing to 
growth via phosphatidyl choline metabolism and osmoprotection  
bifA PA4367 7 Cyclic-di-GMP phosphodiesterase, inversely regulates biofilm formation 
mexA PA0425 7 Membrane fusion protein from MexAB-OprM efflux pump, antibiotic resistance, virulence 
pcoA PA2065 7 Copper resistance 
PA4469 PA4469 7 Hypothetical protein encoded by a gene in same operon as and upstream of sodM 
(superoxide dismutase; response to oxidative stress) 
rbdA PA0861 7 Cyclic-di-GMP phosphodiesterase, modulation of biofilm dispersal, negative regulation of 
Pel production 
pilJ PA0411 6 Methyl accepting chemotaxis receptor-like protein involved in twitching motility and 
biofilm formation 
oprM PA0427 6 Outer membrane protein from MexAB-OprM efflux pump, antibiotic resistance, virulence 
oprF PA1777 6 Major porin, biofilm formation 
chpA PA0413 5 Chemotaxis-like chemosensory protein involved in twitching motility 
fimV PA3115 5 Peptidoglycan-binding protein, promotes type IV pilin assembly, twitching motility 
ladS PA3974 5 Sensor kinase, implicated in switch between acute and chronic infection 
mutL PA4946 5 Mismatch repair system, DNA repair, mutation can lead to mutator phenotype 
gmd PA5453 5 GDP-mannose 4,6-dehydratase,  
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mexS PA2491 5 Mutations promote MexT-dependent mexEF-oprN expression and multidrug resistance 
pchE PA4226 5 Pyochelin synthesis  
PA0054 PA0054 5 Hypothetical protein 
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Pseudomonas aeruginosa adaptation and diversification in the non-Cystic Fibrosis 
bronchiectasis lung  
 
Yasmin Hilliam, Matthew P. Moore, Iain L. Lamont, Diana Bilton, Charles S. Haworth, 
Juliet Foweraker, Martin J. Walshaw, David Williams, Joanne L. Fothergill, Anthony 
De Soyza, Craig Winstanley 
 
Supplementary Methods 
 
Isolation of P. aeruginosa from sputum samples 
All samples were cultured for routine quantitative microbiology. Sputum was homogenised 
with equal parts of 0.1% (v/v) dithiothreitol, and the homogenised sample was diluted in 
sterile distilled water to 1 in 200 and 1 in 10,000. Both dilutions were spread by Whitley 
Automatic Spiral Plater (WASP) onto agar plates.  Cultures on Columbia blood agar, 
chocolate agar and cysteine lactose electrolyte deficient agar (CLED) were incubated at 37
o
C 
in 5% (v/v) CO2  for up to 48 h. Cultures on Pseudomonas agar plus CFC supplement 
(PCFC)  were incubated at 37
o
C in air for up to 48 h and then checked for small colony 
variants (SCV) after incubating on the bench for up to a further 48 h. Colony forming unit 
(CFU) representatives of up to four colonial morphotypes were sub cultured and stored in 
15% (v/v) Glycerol for  archiving  at -80
o
C. 
 
DNA preparation and genome sequencing  
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Genomic DNA was extracted from isolates using a Promega Wizard Genomic DNA 
Purification Kit, quantified using a Qubit 3.0 fluoromiter (Qubit dsDNA broad range assay 
kit, Life Technologies) and tested for purity using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific).  Library preparation and whole-genome shotgun sequencing was 
performed by the Centre for Genomic Research at the University of Liverpool, UK using 
Illumina short read sequencing technology.  Shotgun libraries were prepared from the 
normalised samples using TruSeq Nano library preparation kit. Following library preparation, 
paired-end sequencing (2 x 100 bp) was performed by multiplexing into one lane of the 
Illumina HiSeq platform and sequenced with SBS V4 chemistry. 
Following processing, the raw Fastq files were trimmed for the presence of Illumina 
adapter sequences using Cutadapt version 1.2.1 [1].  The option –O 3 was used so that the 3ʹ 
end of any reads which match the adapter sequence for 3 bp or more were trimmed. The reads 
were further trimmed using Sickle (https://github.com/najoshi/sickle) version 1.200 with a 
minimum window quality score of 20. Reads shorter than 10 bp after trimming were 
removed. If only one read of a pair passed this filter, it was included in the R0 file, with files 
R1 and R2 containing corresponding paired-end sequences.  Quality filtered and adapter 
trimmed short reads were de novo assembled and scaffolded using the A5 MiSeq assembler 
[2].  Genome assembly quality metrics such as N50, largest contig, and overall number of 
contigs were produced using QUAST [3]. 
 
Core genome SNP phylogeny 
The core genome was extracted using Panseq [4] and was defined as 500 bp fragments of all 
genomes in this study which matched with at least 85% similarity. A phylogenetic tree was 
approximated from core genome polymorphic sites, not including gaps or ambiguous bases 
by maximum likelihood with inner node bootstrap (n = 1000) and 10 discrete gamma 
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categories. All phylogenetic analyses were performed using MEGA6 [5] and visualised using 
the iTOL software [6]. Long branches were reduced for clarity.  
 
Multilocus Sequence Typing 
MLST profiles were extracted based on the pubMLST Pseudomonas aeruginosa scheme 
(http://pubmlst.org/paeruginosa/) using a specific tool (https://github.com/tseemann/mlst).  
It was not possible to extract complete MLST profiles from all genomes.  In the context of 
this study, a lineage is defined on the basis of MLST profile and core genome SNP 
phylogeny. 
 
Whole genome pairwise comparisons 
Pairwise comparisons between assembled genomes were performed using MUMmer 3.0 [7].  
Any positions in the alignment with ambiguous nucleotides were removed.  
 
Read mapping and variant calling  
All genome short read files (fastq) were mapped to reference genome PAO1  [8] using bwa-
075a (mem) [9] producing a sequence alignment map (sam) files which were converted to 
binary alignment map files (bam) using picard tools-1.85 
(https://broadinstitute.github.io/picard/). The reference genome was first indexed and sorted 
using bwa and SAMtools [10] respectively and a sequence dictionary created using picard 
tools-1.85. Variants were called following the Genome Analysis Toolkit (GATK) best 
practices workflow, as follows: duplicates were marked, the bam file indexed and sorted with 
picard tools-1.85, realignment targets created, INDELs realigned with GATK-3.3 [11] and 
variants called with the HaplotypeCaller module. Variants were filtered using vcffilter 
(https://github.com/vcflib/vcflib) with the standard parameters (DP >9, QUAL >10).  
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 Resulting variant call files (vcf) were annotated to predict functional outcomes of variants 
compared with PAO1 genes using SnpEff [12]. Using SAMtools depth any variants within 
genes to which short reads had not aligned to 100% of its length were excluded from further 
analysis, leaving substitutions and short insertions or deletions (INDELs) and eliminating 
genes from functional variant analysis to which reads did not fully align due to sequencing 
error (lack of coverage) or genuine large deletions/complete absence.  
 
Loss of function mutations  
 
Predicted loss of function mutations were inferred to have been acquired independently in the 
population if they differed by position or type between genomes. Where the position and type 
were the same they were inferred to be shared; in genes where a mutation was shared with 
other genomes, further loss of function mutations were assumed to have been acquired since 
the common, ancestral acquisition of the shared mutation.  
 
 
Supplementary Tables: 
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Supplementary Table S1. Bacterial isolates used in this study.  ST refers to the 
designated multilocus sequence type.  *novel shared MLST and they cluster according to 
SNP phylogeny.  Isolates C21-C23 cluster together according to core genome SNP 
phylogeny. Isolates included in the subset of 99 genomes are highlighted in red.  The Mutator 
column indicates the presence of mutations associated with hypermutability (INDEL, causing 
a frameshift or STOP, introduction of a stop codon). Of the 11 isolates carrying such a 
mutation, all but two (B113 and C78) were confirmed as having a hypermutable phenotype 
using assays reported previously [13]. Isolates labelled with the same letter from 
a
 to 
i 
were 
considered to be from the same lineage as each other on the basis of incomplete MLST 
profiles (see Table S2) and clustering by core genome SNP phylogeny (see Figure S1).  
Isolate 
ID 
Center Date Patient ST 
Mutator 
A1 1 09/10/2014 1 17  
A2 1 16/10/2014 2 207  
A3 1 10/10/2014 3 252  
A4 1 10/10/2014 3 252  
A5 1 10/10/2014 3 252  
B3 12 01/11/2008 8 281  
B16 12 25/11/2013 9 253  
B34 12 03/09/2014 11 179  
B37 12 18/01/2012 12 -  
B62 12 03/09/2014 15 -  
B113 12 23/10/2014 18 1328 mutL (INDEL) 
B114 12 11/04/2012 19 198  
B199 12 18/10/2011 32 1182  
A12 1 14/11/2014 35 179  
C2 4 14/10/2009 36 253  
C3 4 25/02/2010 37 260  
C4 4 25/02/2010 37 -
a
  
C5 4 25/02/2010 37 260
 a
  
C6 4 03/03/2010 38 244  
C7 4 23/03/2010 39 244  
C10 4 16/04/2010 40 244  
C8 4 16/04/2010 40 244  
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C9 4 16/04/2010 40 244  
C11 4 19/08/2010 41 282  
C12 4 20/08/2010 42 282  
C13 4 20/08/2010 42 27
 b
  
C14 4 20/08/2010 42 27
 b
  
C15 4 20/08/2010 42 27
 b
  
C16 4 20/08/2010 42 -
b
  
C17 4 20/08/2010 42 -
 b
  
C18 4 15/04/2011 43 - mutL (STOP) 
C20 4 01/07/2011 44 878  
C21 15 14/04/2009 45 -
c
  
C22 15 14/04/2009 45 -
 c
  
C23 15 14/04/2009 45 -
 c
  
C25 15 20/05/2009 46 253  
C29 15 03/06/2009 48 252  
C30 15 04/06/2009 49 252  
C31 15 25/08/2009 50 -
 d
 mutL (INDEL) 
C32 15 25/08/2009 50 -
d
  
C33 15 25/08/2009 50 -
 d
  
C36 15 21/05/2010 52 253  
C42 15 12/07/2010 54 309  
C43 15 28/07/2010 55 108  
C44 15 28/07/2010 55 108  
C45 15 28/07/2010 55 108  
C49 15 22/02/2011 58 395  
C51 15 23/02/2011 59 683  
C54 15 15/06/2011 61 1342  
C55 5 26/06/2009 62 -
 e
  
C56 5 26/06/2009 62 -
e
  
C57 5 26/06/2009 62 -
 e
  
C58 5 26/06/2009 62 -
 e
  
C59 5 26/06/2009 62 -
 e
  
C60 5 26/06/2009 62 -
 e
  
C61 5 17/11/2009 63 620  
C63 3 02/09/2009 64 27  
C64 3 25/11/2009 65 274  
C65 3 25/11/2009 65 274  
C66 3 25/11/2009 65 274  
C67 3 25/11/2009 65 274  
C68 3 25/11/2009 65 274  
C69 3 12/05/2010 66 -  
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C71 9 04/09/2009 67 968  
C73 9 05/11/2010 68 17  
C74 9 03/12/2010 69 1202 mutL (STOP) 
C76 2 12/05/2009 70 253  
C77 2 03/07/2009 71 308  
C78 2 14/07/2009 72 840 mutL (INDEL) 
C79 2 14/07/2009 72 620
 f
 mutL (STOP) 
C80 2 14/07/2009 72 620
 f
  
C81 2 14/07/2009 72 620
 f
  
C82 2 14/07/2009 72 620
 f
  
C83 2 14/07/2009 72 -
f
  
C84 2 14/07/2009 72 620
 f
  
C85 2 06/08/2009 73 -
g
  
C86 2 06/08/2009 73 308  
C87 2 06/08/2009 73 179
 g
  
C88 2 15/12/2009 74 1251  
C89 2 25/03/2010 75 1239  
C91 2 13/01/2011 76 253  
C92 2 01/02/2011 77 252  
C94 10 03/07/2009 78 395  
C95 10 29/07/2009 79 253  
C96 10 29/07/2009 79 253  
C97 10 29/07/2009 79 253  
C98 10 29/07/2009 79 253  
C99 10 29/07/2009 79 253  
C100 10 13/10/2009 80 612  
C101 10 21/10/2009 81 -
 h
  
C102 10 21/10/2009 81 -
h
  
C103 10 21/10/2009 81 -
 h
  
C104 13 16/05/2009 82 179  
C105 13 25/07/2009 83 840  
C106 13 11/08/2009 84 -
i
  
C107 13 11/08/2009 84 253  
C108 13 11/08/2009 84 179
 i
  
C109 13 11/08/2009 85 840  
C110 13 11/08/2009 85 179  
C111 13 11/08/2009 85 179  
C112 13 11/08/2009 85 179  
C114 13 05/12/2009 86 179  
C115 13 05/12/2009 86 179  
C116 13 04/06/2010 87 871  
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C117 13 04/06/2010 87 871  
C118 13 04/06/2010 87 871  
C119 7 23/01/2010 88 -  
C120 7 29/01/2010 89 -  
C123 7 02/04/2010 90 27 mutS (INDEL) 
C124 7 08/04/2010 91 1753  
C125 7 29/04/2010 92 253  
C126 7 29/04/2010 92 253  
C127 7 29/04/2010 92 164 mutS (INDEL) 
C128 7 29/04/2010 92 164  
C129 7 29/04/2010 92 871 mutL (INDEL) 
C131 7 08/05/2010 93 253  
C133 7 28/05/2010 94 253 mutS (INDEL) 
C134 7 19/12/2010 95 253 mutS (INDEL) 
C135 14 02/11/2009 96 160  
C137 14 16/04/2010 97 260  
C139 14 08/09/2010 98 2102  
C141 14 01/10/2010 99 2102  
C142 14 11/02/2011 100 252  
C143 8 08/07/2010 101 253  
C144 8 08/07/2010 101 253  
C145 8 08/07/2010 101 253  
C146 8 25/06/2010 102 395  
C147 8 25/06/2010 102 395  
C148 8 25/06/2010 102 395  
C149 8 22/03/2011 103 108  
C150 6 27/08/2010 104 253  
C151 6 03/03/2011 105 1244  
C153 6 07/04/2011 106 155  
C155 11 04/12/2010 107 1211  
C156 16 16/11/2010 108 260  
C158 16 03/12/2010 109 155  
C159 16 09/12/2010 110 260  
C160 16 09/12/2010 111 1244  
C161 16 03/03/2011 112 110  
C164 16 08/12/2010 113 -  
C167 16 21/04/2011 114 296  
C168 16 21/12/2010 115 17  
A19 1 16/12/2014 120 -  
A163 1 19/05/2015 137 146  
A36 1 17/02/2015 137 146  
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A46 1 07/04/2015 147 17  
A48 1 07/04/2015 147 17  
A52 1 07/04/2015 147 17  
A53 1 07/04/2015 147 17  
A54 1 07/04/2015 147 17  
A55 1 07/04/2015 147 17  
A56 1 07/04/2015 147 17  
A58 1 07/04/2015 147 17  
A60 1 07/04/2015 147 17  
A70 1 07/04/2015 147 17  
A71 1 07/04/2015 147 17  
A72 1 07/04/2015 147 17  
A73 1 07/04/2015 147 17  
A75 1 07/04/2015 147 17  
A76 1 07/04/2015 147 17  
A100 1 07/04/2015 148 17  
A106 1 07/04/2015 148 175  
A107 1 07/04/2015 148 175  
A77 1 07/04/2015 148 175  
A78 1 07/04/2015 148 17  
A80 1 07/04/2015 148 175  
A81 1 07/04/2015 148 17  
A82 1 07/04/2015 148 17  
A85 1 07/04/2015 148 175  
A86 1 07/04/2015 148 175  
A90 1 07/04/2015 148 175  
A91 1 07/04/2015 148 175  
A92 1 07/04/2015 148 175  
A95 1 07/04/2015 148 175  
A97 1 07/04/2015 148 175  
A119 1 15/05/2015 149 667  
A122 1 15/05/2015 149 667  
A123 1 15/05/2015 149 667  
A126 1 15/05/2015 149 667  
A130 1 15/05/2015 149 667  
A134 1 15/05/2015 149 667  
A137 1 15/05/2015 149 667  
A141 1 15/05/2015 149 667  
A144 1 15/05/2015 149 667  
A147 1 15/05/2015 149 667  
A148 1 15/05/2015 149 667  
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A151 1 15/05/2015 149 667  
A154 1 15/05/2015 149 667  
A156 1 15/05/2015 149 667  
      
 
 
Supplementary Table S2.  MLST profiles of isolates where incomplete profiles were 
obtained or the MLST profile was novel. 
Isolate ST Closest ST 
Pseudomonas aeruginosa MLST 
loci allele numbers 
acs aro gua mut nuo pps trp 
A19 NF 92 or 261 105 5 30 - 1 4 14 
B37 Novel 107 4 3 27 12 7 128 
B62 NF 1404 16 - 6 3 4 7 1 
C101 NF 303 (4 loci) 16 - 12 18 3 4 9 
C102 NF 304 (4 loci) 16 - 12 18 3 4 9 
C103 NF 305 (4 loci) 16 - 12 18 3 4 9 
C106 NF 156,179,353,1494 (6 loci) - 27 28 3 4 13 7 
C119 Novel 5 1 109 3 1 1 47 
C120 Novel 17 5 11 5 4 29 2 
C164 NF 1240,1985 (4 loci) 28 5 46 5 1 - 61 
C16 NF 27,120,2314 (5 loci) 6 - 6 113 4 6 7 
C17 NF 27,120,2314 (5 loci) 6 - 6 113 4 6 7 
C18 NF 
158,179,180,1496,2063,2109 (6 
loci) 36 27 28 - 4 13 7 
C21 Novel 22 6 1 3 1 76 1 
C22 Novel 22 6 1 3 1 76 1 
C23 Novel 22 6 1 3 1 76 1 
C31 NF 155,677,1276 (5 loci) 28 5 36 - 3 13 7 
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C32 NF 155,677,1276 (5 loci) 28 5 36 - 3 13 7 
C33 NF 155,677,1276 (5 loci) 28 5 36 - 3 13 7 
C4 NF 260 (6 loci) 14 5 - 7 4 13 7 
C55 Novel 28 5 11 11 15 75 1 
C56 Novel 28 5 11 11 15 75 1 
C57 Novel 28 5 11 11 15 75 1 
C58 Novel 28 5 11 11 15 75 1 
C59 Novel 28 5 11 11 15 75 1 
C60 Novel 28 5 11 11 15 75 1 
C69 NF 1707, 2055 (6 loci) 16 24 1 149 4 - 19 
C83 NF 620 (6 loci) 9 7 63 13 8 - 8 
C85 NF 156, 179, 353, 1494 (6 loci) - 27 28 3 4 13 7 
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Table S3. Clonal lineages isolated from multiple patients within individual centres.   Sets 
of isolates from different patients attending the same centre are grouped by clonal lineage. 
For each such group, whole genome pairwise comparisons were carried out to determine the 
number of variant SNPs and INDELs.  *These isolates share a novel MLST profile and they 
cluster according to SNP phylogeny.   
 
 
Isolate Centre Isolation date Patient MLST Comparison SNPs INDELs 
C6 4 03/03/2010 38 244 
     C6-C7 
C6-C8 
C6-C9 
C6-C10 
C7-C8 
C7-C9 
C8-C9 
C7-C10 
C8-C10 
C9-C10 
      179 
3790 
3733 
3833 
3736 
3714 
281 
3929 
603 
515 
        8 
       79 
       74 
62 
82 
75 
5 
65 
14 
11 
C7 4 23/03/2010 39 244 
C8 4 16/04/2010 40 244 
C9 4 16/04/2010 40 244 
C10 4 16/04/2010 40 244 
        
C11 4 19/08/2010 41 282 C11-C12 340 8 
C12 4 20/08/2010 42 282    
        
C29 15 03/06/2009 48 252 C29-C30 168 3 
C30 15 04/06/2009 49 252    
C25 15 20/05/2009 46 253 C25-C36 3428 43 
C36 15 21/05/2010 52 253    
C91 2 13/01/2011 76 253 C76-C91 846 5 
C76 2 12/05/2009 70 253    
        
C77 2 03/07/2009 71 308 C77-C86 277 1 
C86 2 06/08/2009 73 308    
C105 13 25/07/2009 83 840 C105-C109 131 8 
        
C109 13 11/08/2009 85 840    
C104 13 16/05/2009 82 179 
C104-C108 
C104-C110 
C104-C111 
C104-C112 
C104-C114 
C104-C115 
C108-C110 
C108-C111 
C108-C112 
10,551 
2863 
2765 
1913 
6795 
6972 
4780 
4852 
3780 
114 
39 
52 
25 
96 
105 
78 
66 
62 
C108 13 11/08/2009 84 179 
C110 13 11/08/2009 85 179 
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C111 13 11/08/2009 85 179 
C108-C114 
C108-C115 
C110-C111 
C110-C112 
C110-C114 
C110-C115 
C111-C112 
C111-C114 
C111-C115 
C112-C114 
C112-C115 
C114-C115 
 
10,963 
10,833 
176 
198 
3115 
3107 
148 
2838 
2789 
1941 
1895 
281 
136 
133 
8 
7 
40 
45 
4 
43 
57 
29 
31 
4 
C112 13 11/08/2009 85 179 
C114 13 05/12/2009 86 179 
C115 13 05/12/2009 86 179 
        
C125 7 29/04/2010 92 253 C125-C126 
C125-C131 
C125-C133 
C125-C134 
C126-C131 
C126-C133 
C126-C134 
C131-C133 
C131-C134 
C133-C134 
736 
1159 
872 
817 
9636 
5847 
5883 
3486 
3400 
330 
27 
22 
22 
21 
99 
71 
70 
40 
38 
4 
C126 7 29/04/2010 92 253 
C131 7 08/05/2010 93 253 
C133 7 28/05/2010 94 253 
C134 7 19/12/2010 95 253 
        
C156 16 16/11/2010 108 260 C156-C159 160 3 
C159 16 09/12/2010 110 260 
        
C139 14 08/09/2010 98 ST2102 C139-C141 177 3 
C141 14 01/10/2010 99 ST2102 
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Supplementary Table S4 and Figure S1 are provided in additional files: 
Table S4. Clone-specific deletions, relative to PAO1 
Figure S1.  Core genome SNP phylogeny showing the distribution of bronchiectasis isolates.  
The figure shows analysis of the genomes of all bronchiectasis isolates used in this study 
(highlighted in blue) alongside 331 genomes from Kos et al. [14] and the genomes of 
commonly studied strains PAO1 (labelled PAO1107), PA14 (UCBPPPA14109), PA7 and 
LESB58.  Line colours indicate the two major clusters of P. aeruginosa (I, green; II, blue) as 
well as those isolates not clustering in the two main groups (red). 
Figure S2. Distribution of loss of function mutations.  For the genes listed in Table 2, where 
the number of independent occurrences of a loss of function mutation was equal to or greater 
than five, the Figure indicates the number of isolates carrying mutations in 0, 1, 2, 3, 4, 5 or 6 
of these genes. 
 
 
Table S5. Full list of loss of function mutations identified by variant calling.  Available via 
the Figshare link https://figshare.com/s/ff426bae75ee64804aa1 
Table S6. Loss of function mutations present in each bronchiectasis isolate genome.  For the 
genes listed in Table 2, where the number of independent occurrences of a loss of function mutation 
was equal to or greater than five, the genes carrying such mutations are shown for each of the 
bronchiectasis isolates.  17 of the 99 isolates carried none of these mutations.  It is worth noting that 
isolates found co-infecting individual patients did not share the same mutation profile (C125, C127 
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and C129 in patient 92; C12 and C13 in patient 42; C78 and C79 in patient 72; C86 and C87 in patient 
73; C107 and C108 in patient 84; C109 and C110 in patient 85; A100 and A106 in patient 148). 
Isolate 
Number 
of Table2 
genes 
with loss 
of 
function 
mutations Mutations 
C125 6 PA4469  mexS  ladS  rbdA  betT2  mexA 
C74 6 PA4469  mexS  chpA  mutL  pchE  mexB 
C87 6 PA4469  bifA  pchE  ladS  chpA  mexA 
C123 5 rbdA  PA4469  pchE  mexS  oprM 
 C116 5 PA4469  mucA  mexB  oprF  pchE 
 C88 5 mucA  pcoA  betT2  oprF  mexA 
 C100 4 rbdA  PA4469  mucA  chpA 
 C79 4 rbdA  PA4469  mucA  mutL 
 C133 4 rbdA  mucA  pchE  oprM 
 C95 4 rbdA  mucA  oprM  pcoA 
 B16 4 rbdA  mucA  mexB  fimV 
 C21 4 PA4469  mucA  mexB  pcoA 
 C31 4 PA4469  mucA  mutL  fimV 
 C110 4 PA4469  mucA  oprF  mexA 
 C108 4 mexB  chpA  mucA  betT2 
 C129 4 mucA  mexB  oprF  gmd 
 C134 3 rbdA  mucA  oprM 
 C143 3 rbdA  mucA  mexB 
 C2 3 rbdA  mexB  chpA 
 A119 3 PA4469  oprF  pcoA 
 A46 3 PA4469  mucA  oprF 
 C63 3 betT2  ladS  fimV 
 C114 3 mexB  pchE  betT2 
 A163 3 mucA  mexB  gmd 
 C149 3 mucA  pchE  oprM 
 C55 3 mucA  pilJ  oprF 
 B113 3 pilJ  mutL  pcoA 
 C124 2 PA0054  mucA 
 C146 2 PA0054  mexA 
 C49 2 PA0054  betT2 
 C51 2 PA0054  rbdA 
 B114 2 rbdA  mexB 
 C25 2 rbdA  mexB 
 C36 2 rbdA  mucA 
 C86 2 rbdA  mexA 
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C20 2 rbdA  pilJ 
    C137 2 rbdA  PA4469 
 C6 2 PA4469  mexS 
    C7 2 PA4469  mexS 
 C135 2 mucA  mexS 
    C61 2 PA4469  mexA 
 C42 2 PA4469  oprF 
    A100 2 PA4469  fimV 
 B62 2 PA4469  pilJ 
    C131 2 betT2  ladS 
 B34 2 bifA  betT2 
    C12 2 bifA  betT2 
 C11 2 bifA  betT2 
    A1 2 bifA  ladS 
 B3 2 fimV  pcoA 
    C167 2 mexA  gmd 
 C3 2 pilJ  mexB 
    A2 2 mucA  mexB 
 C153 2 mexB  oprF 
    C158 2 mexB  oprF 
 C161 2 mucA  pcoA 
    C18 2 oprM  mutL 
 C155 2 pilJ  oprM 
    C94 1 PA0054 
 C120 1 rbdA 
     A3 1 rbdA 
 C77 1 rbdA 
     C91 1 rbdA 
 C69 1 rbdA 
     C156 1 rbdA 
 C159 1 rbdA 
     C107 1 betT2 
 C119 1 bifA 
     A106 1 bifA 
 C43 1 bifA 
     B199 1 gmd 
 C89 1 gmd 
     C168 1 gmd 
 A12 1 mexB 
     C54 1 mexB 
 C92 1 mucA 
     C10 1 mucA 
 C73 1 mucA 
     C142 1 mucA 
 C76 1 mucA 
     B37 1 mucA 
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C101 1 oprM 
      
Table S7.  The presence or absence of virulence genes amongst the non-CF BE isolate 
genomes.  Available via the Figshare link https://figshare.com/s/626a59cfd94b13e5cf71 
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